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MaxQuant is a quantitative proteomics software package designed for analyzing large mass spectrometric data sets. It is
speciﬁcally aimed at high-resolution mass spectrometry (MS) data. Currently, Thermo LTQ-Orbitrap and LTQ-FT-ICR instruments are
supported and Mascot is used as a search engine. This protocol explains step by step how to use MaxQuant on stable isotope
labeling by amino acids in cell culture (SILAC) data obtained with double or triple labeling. Complex experimental designs, such as
time series and drug-response data, are supported. A standard desktop computer is sufﬁcient to fulﬁll the computational
requirements. The workﬂow has been stress tested with more than 1,000 liquid chromatography/mass spectrometry runs in a single
project. In a typical SILAC proteome experiment, hundreds of thousands of peptides and thousands of proteins are automatically and
reliably quantiﬁed. Additional information for identiﬁed proteins, such as Gene Ontology, domain composition and pathway
membership, is provided in the output tables ready for further bioinformatics analysis. The software is freely available at the
MaxQuant home page.
INTRODUCTION
Mass spectrometry-based proteomics1 has become a very
data-intensive science, especially since high-resolution Fourier trans-
form mass spectrometers have become widespread2,3. For instance,
assume there would be 5,000 high-mass precision instruments,
e.g., LTQ-Orbitraps4,5, running worldwide without downtime,
each performing 10 liquid chromatography/mass spectrometry
(LC/MS) runs per day and generating 1 GB of raw data per run.
Together, this would result in an annual data production rate of
18 PB (¼ 1.8 1016 bytes), which is more than the four experiments
in the large hadron collider at CERN—the prime example for data-
intensive experimental science—will produce per year (http://
lcg.web.cern.ch/LCG/). Without any doubt, this situation calls for
solid, efﬁcient and standardized data-processing workﬂows that are
widely applicable in quantitative proteomics. In ref. 6, we describe
such a computational platform called MaxQuant, which is targeted
at high-resolution quantitative data obtained with stable isotope
labeling by amino acids in cell culture (SILAC)7,8 and which we
have already successfully applied to a wide range of biological
problems9–15. Although the novel algorithmic concepts are
explained in detail in ref. 6, here we give the step-by-step instruc-
tions how to analyze large-scale proteomic data with MaxQuant.
Two example data sets are provided, which allow re-analysis of the
data from two recent papers of our laboratory6,14,16.
SILAC proteome experiments can be performed in many alter-
native ways, differing for instance in additional protein or peptide
fractionation or in the kind of stable isotope labels used.
Pre-fractionation of proteins, e.g., by gel electrophoresis, or a
separation of digested peptides, e.g., with immobilized pI strips17,
is compatible with theMaxQuant computational workﬂow. SILAC
data from double- or triple-labeling18 experiments can be ana-
lyzed. Although a standard procedure is to label arginine and lysine
when digesting proteins with trypsin, the kind of amino acids that
are labeled as well as the atoms within the amino acids that are
replaced by stable heavy isotopes can be freely conﬁgured and may
be adapted to any existing combination of labels. In addition to
simple treatment/control SILAC comparisons, experiments with a
more complex design can be analyzed, such as replicate measure-
ments, SILAC time series with common reference points, label
switches, multi-sample comparisons, and more. Furthermore,
interaction data in the form of SILAC pulldowns19 can be
analyzed. MaxQuant will in each case automatically assemble a
matrix of SILAC ratios with rows corresponding to proteins and
columns to different ‘samples’ or ‘conditions’ facilitating cross-
experiment comparison of protein ratios. Thus, it is preferable in
most situations to analyze data from different samples together in
one MaxQuant project, so as to enable comparison of quantitative
information directly. This is also a precondition for reliable control
of protein false discovery rate (FDR).
Figure 1 shows an overview of the computational pipeline and
the types of ﬁles that are exchanged. Raw ﬁles are generated by the
instrumentation software and transferred to the local computer
where they are loaded into the ‘Quant’module. It performs all tasks
that can be done before knowing the identity of peptides. In
particular, the assembly of isotope patterns into SILAC pairs is
already done here, before the submission of data to a tandem mass
spectrometry (MS/MS) search engine. An advanced three-
dimensional peak and isotope pattern detection is also carried
out in this module. Output ﬁles are generated containing processed
MS/MS spectra (‘msm’ ﬁles) bundled together from all LC/MS runs
analyzed together, ready for submission to the Mascot search
engine20. A parameter ﬁle containing the search engine parameters
is also created (‘par’ ﬁle), facilitating the submission of MS/MS
spectra with Mascot Daemon (see below). The ‘Identify’ module
takes the search engine results, the raw ﬁles (as well as intermediate
results from the ‘Quant’ module), performs integration and statis-
tical validation, assembles peptides into proteins, quantiﬁes
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proteins and writes out several tables containing the results as tab-
separated text ﬁles (.txt). These can be uploaded for browsing and
downstream bioinformatics analysis into programs such as Micro-
soft Ofﬁce Excel, R in conjunction with Bioconductor, Spotﬁre,
Matlab and the like.
The MaxQuant website will be expanded as a repository of tools
and documents supporting the use of MaxQuant. Presently, we
provide protein sequence databases for the most common organ-
isms inMaxQuant-compatible formats ready for upload toMascot.
In addition, here we describe and provide a program (‘Sequence
Reverser’) that allows creating a MaxQuant-compatible FASTA ﬁle
given the user’s own organism-speciﬁc protein list. Furthermore, a
list of common contaminants—which can be expanded or conﬁg-




.A personal computer (PC) with at least 2 GB of RAM m CRITICAL At least a
dual-core processor is recommended. Most computational parts scale with
the number of available computing cores because of parallelization.
.Local storage is used for all raw ﬁles belonging to a project, and about half
of this size for intermediate results. An external disc connected through USB
2.0 would be sufﬁcient
Software requirements
.32 bit versions of Windows XP or Windows Vista operating systems
m CRITICAL ‘Regional and Language Options’ have to be set to English.
. .NET Framework 2.0 is to be installed
.Thermo Fisher Scientiﬁc Xcalibur software m CRITICALVersion must be
compatible with your .raw ﬁles.
.Access to a Mascot (Matrix Science) server (currently version 2.2)
.Mascot Daemon installed on your local computer. Currently, MaxQuant uses
Mascot (version 2.2, Matrix Science) as MS/MS search engine. For
convenient and automatic submission of .msm and .par ﬁles generated by
Quant, we recommend Mascot Daemon, a client application included in the
Mascot purchase
.Microsoft Ofﬁce Excel 2007. Recommended for browsing the result ﬁles
m CRITICAL Older versions of Excel will likely lead to problems due to
limitations in allowed numbers of rows and columns.
.Sequence database (see EQUIPMENT SETUP)
.MaxQuant (see EQUIPMEMT SETUP)
EQUIPMENT SETUP
MaxQuant software installation Go to MaxQuant home page and
navigate to the ‘Downloads’ section. Please read the software license agreement
carefully and stop at this point if you do not agree to its terms and conditions.
When downloading MaxQuant you will receive a zipped ﬁle containing
all necessary binaries and conﬁguration ﬁles. Unzip this ﬁle (e.g., with WinZip)
and store the resulting folder named ‘MaxQuant’ anywhere on the computer
that one is going to use for the computations. No installation script needs to be
executed. After saving the ‘MaxQuant’ folder, one needs to adapt the ﬁles in the
folder ‘MaxQuant\conf ’ to your local environment. The ﬁles ‘enzymes,’
‘mod_ﬁle,’ ‘mascot.dat’ and ‘unimod.xml’ are copies of the corresponding
ﬁles in the conﬁguration folder of Mascot installation. These ﬁles have to
be identical in the MaxQuant installation and on the Mascot server. Whenever
anything is changed in the conﬁguration of theMascot server, e.g., modiﬁcations
or sequence databases are added, one has to copy those ﬁles from the
Mascot server into the MaxQuant installation, because local editing will lead
to malfunction. SILAC labels can be conﬁgured in the ﬁle ‘labels.txt,’ which
is a tab-separated text ﬁle and may be edited with Microsoft Ofﬁce Excel.
Table 1 contains some examples of deﬁnitions for some standard SILAC labels.
In the ‘Composition’ column, the labeled form of the amino acid
is speciﬁed by its empirical formula. For this purpose, 13C, 2H and 15N are
represented by ‘Cx,’ ‘Hx’ and ‘Nx,’ respectively. The ‘Mascot Name’ column
contains the modiﬁcation as it appears in the ‘mod_ﬁle.’ Note that in
the ‘mod_ﬁle’ the amino acid type (e.g., ‘R’) is automatically appended at
the end of the name in brackets. ‘Short Name’ deﬁnes how the label is denoted
in the graphical user interface of Quant.
Sequence database We recommend using a species-speciﬁc protein
sequence database that includes all predicted proteins from an organism with
fully sequenced genome. For instance, when analyzing human data, the
human International Protein Index database21 may be used, or, alternatively,
all human protein entries contained in Uniprot22, including the TrEMBL part,
or all ENSEMBL23 proteins. Redundancy of protein sequences does not mat-
ter at this point, as it will be dealt with at a later stage by the software, when
assembling the identiﬁed peptides to proteins. MaxQuant validates scoring
statistics on the basis of the hits to reversed protein entries in a target-decoy
database24. Therefore, it is necessary to include a reversed version for each
original entry in the protein database FASTA ﬁle. Reversed entries have to be
indicated by a recognizable preﬁx to the protein ID, e.g., ‘REV_’. In addition,
a set of common contaminant proteins can be included, also having a speciﬁc
















































Figure 1 | Overview of the computational workﬂow. It consists of ﬁve steps:
the ﬁrst step—data acquisition—is performed by the vendor software of the
mass spectrometer used; in the second step, the ‘Quant.exe’ module of
MaxQuant detects peak features and quantiﬁes peptides; in the third step, a
search engine (here Mascot) associates fragment spectra with amino acid
sequences; in the fourth step, the ‘Identify.exe’ module of MaxQuant validates
and scores peptide identiﬁcations, assembles them to protein identiﬁcations
and determines protein ratios; and in the ﬁfth step, downstream bioinformatic
analysis is performed by general purpose software (spreadsheets), statistical
packages or bioinformatic packages.
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keratins or of abundant proteins from bovine serum if applicable. Visit the
accompanying web page for pre-built MaxQuant-compatible FASTA ﬁles
for the most common organisms and for downloading the program
Sequence Reverser for reversing each entry and adding contaminants of
arbitrary protein sequence collections. The FASTA ﬁle should be uploaded to
the Mascot server in the normal way as described in the Mascot manual.
A copy of exactly the same ﬁle needs to be available locally on the computer
where MaxQuant is running.
PROCEDURE
Preparation of data ﬁles
1| Copy all Xcalibur .raw ﬁles belonging to a project to a single folder on a local computer. The ﬁles may reside on an
external hard drive.
m CRITICAL STEP MaxQuant currently supports only ﬁles produced by LTQ-FT-ICR and LTQ-Orbitrap. Additionally, the current
version of the Xcalibur software can only open ‘.raw’ ﬁles smaller than 2 GB. Therefore, we suggest recording the MS/MS spectra in
the centroid mode, which will keep ﬁle size sufﬁciently small for normal length gradients.
2| Make sure that there is sufﬁcient storage space available on the hard disc containing the raw data. In addition to the raw
ﬁles, there should be at least half of this space available for intermediate results generated by MaxQuant during the calculations.
Quant.exe: feature detection and peptide quantiﬁcation
3| Start Quant.exe by double clicking on it. The program is in the ‘MaxQuant’ folder on your local PC.
4| Go to the ‘Raw ﬁles’ tab. The location of this tab and those of the tabs described in later steps are shown in Figure 2.
5| Load the Xcalibur .raw ﬁles to be analyzed by clicking the ‘Select ﬁles’ button. Alternately, select all the .raw ﬁles
in a folder with the ‘Select folder’ button. The raw ﬁles will
appear in the main table.
m CRITICAL STEP All raw ﬁles to be analyzed should be in the
same folder.
m CRITICAL STEP MaxQuant’s strength is in the analysis of large
numbers of LC/MS runs. When analyzing only very few LC/MS
runs, the statistical evaluation of peptide identiﬁcations may
suffer, as a sufﬁciently high number of identiﬁed MS/MS spectra
are required to determine histograms used in intermediate steps
of the calculation. Although it is possible to analyze even
single runs separately with practically usable results, it is
recommended to analyze together at least 10 LC/MS runs of
reasonably high peptide complexity.
6| Select the number of threads that will be run in parallel
by MaxQuant. Each ﬁle will be analyzed by one process and the
use of multiple processes will considerably shorten the time of
analysis. If the number of threads selected is the same or
higher than the number of available computing cores, the
computer will be very busy and it will hardly be possible to use
it for other purposes during the processing time.
7| Go to the ‘Parameters’ tab.
8| Choose the type of instrument that has produced the
ﬁles. In the current MaxQuant version, ‘FT’ and ‘Orbitrap/FT
Ultra’ can be chosen.
9| Select the following types of SILAC experiment:
TABLE 1 | The default content of the SILAC label conﬁguration ﬁle ‘labels.txt’.
Composition Mascot name Short name Amino acid
Cx6H12N4O Arginine-13C6 (R-13C6) (R) Arg6 R
Cx6H12Nx4O Arginine-13C615N4 (R-full) (R) Arg10 R
C6H8Hx4N2O Lysine (D4) (K) Lys4 K
Cx6H12N2O Lysine-13C6 (K-13C6) (K) Lys6 K
Cx6H12Nx2O Lysine-13C615N2 (K-full) (K) Lys8 K
C6H8Hx3NO Leucine (D3) (L) Leu3 L

















Figure 2 | The graphical user interface of the Quant module. The upper panel
shows the ‘Raw ﬁles’ tab, whereas in the lower panel, the ‘Parameters’ tab is
shown. The positions in the user interface of Quant.exe that correspond to
numbered steps in the procedure are indicated by the step number.
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(a) ‘Singlets’ if no isotopic labeling was used; peptides and protein are identiﬁed and no quantiﬁcation will be provided.
(b) ‘Doublets’ (default selection) in case of a double SILAC labeling; a ‘Heavy labels’ panel will appear.
(c) ‘Triplets’ for a triple SILAC labeling; a ‘Medium labels’ and a ‘Heavy labels’ panel will appear.
Select the appropriate labeled amino acids used in the SILAC experiment in the appropriate panels. It is assumed that in the
‘Light’ SILAC state, all amino acids have a natural isotopic composition. Note that the available labels are read from the
labels.txt ﬁle in the ‘conf’ folder mentioned above.
10| Specify the maximum number of labeled amino acids (‘Max. labeled AAs’) a peptide can have to be detected by Quant.
11| Add variable modiﬁcations by selecting the desired modiﬁcation on the left of the ‘Variable modiﬁcations’ panel and
click on the right arrow button. The modiﬁcation will then appear in the right panel. Per default oxidation of methionine and
N-terminal protein acetylation are used. To remove a modiﬁcation, select the modiﬁcation to be removed in the right panel
and click on the left arrow button. Variable modiﬁcations may or may not be present on a speciﬁc residue or a terminus.
m CRITICAL STEP Modiﬁcations related to SILAC labeling must not be speciﬁed here, as they are already automatically taken
care of by deﬁning the SILAC experiment type in Step 9.
m CRITICAL STEP Mascot, and consequently MaxQuant, only allows up to nine variable modiﬁcations. It is important to
note that SILAC modiﬁcations (e.g., Arg10 and Lys8) as selected in the SILAC panels are de facto variable modiﬁcations when the
database search is performed on the unpaired isotope patterns. In general, large numbers of variable modiﬁcations should be
avoided because if they do not occur sufﬁciently often, they only tend to decrease the number of identiﬁcations at ﬁxed FDR, and
they will increase search times considerably (combinatorial explosion)25.
12| Select or deselect, as desired, any ‘Fixed modiﬁcations’ in the same way as described for variable modiﬁcations.
Fixed modiﬁcations are applied to every occurrence of the speciﬁed residue or the terminus. For example, during the digestion
reaction, iodoacetamide was used to alkylate cysteines, and to select ‘Carbamidomethyl (C)’ as ﬁxed modiﬁcation.
13| Choose from the ‘Database’ box menu the protein sequence database desired to be used in the Mascot search. Select the
‘Enzyme’ speciﬁcity according to the enzyme used during protein digestion. Select the maximum number of missed cleavages a
peptide can have in order to be found in the Mascot search.
m CRITICAL STEP Selections of ‘Max.-labeled AAs,’ ‘Enzyme’ and ‘Max.-missed cleavages’ are not independent. For most
efﬁcient application of SILAC, the choice of labeled amino acids should coincide with the enzyme speciﬁcity. In that case, the
maximum number of labeled amino acids should be one more than the number of maximum missed cleavages. We then
recommend 3 and 2, respectively.
14| Specify the maximum mass deviation allowed for the fragment ions (‘MS/MS tol.’). Units can be selected as Dalton
(Da) or parts per million (ppm). For a calibrated LTQ, a tolerance of 0.5 Da is recommended26. The maximum mass
deviation for parent ion masses is determined by MaxQuant on the basis of the achieved mass accuracy and does not need
to be speciﬁed.
15| Select the number of most intense peaks per 100 Da in which Quant will be retained after processing of MS/MS spectra
(‘Top MS/MS peaks per 100 Da’) for the Mascot database search. By default we use six, which is a good balance between scoring
correct fragment peaks and suppression of noise.
16| Set the size limit in megabytes for the .msm ﬁles that Quant creates, containing the processed MS/MS spectra ready for
submission to Mascot (‘Max. msm ﬁle size (MB)’). If a ﬁle exceeds this limit, it will be split into two or more parts. A maximum
ﬁle size of 350 MB is recommended, as for larger ﬁles occasional crashes of Mascot searches have been observed. Splitting does
not affect results, as Identify.exe assembles data from all Mascot searches.
17| Go back to the ‘Raw ﬁles’ tab, press the ‘Start’ button and wait for the program to ﬁnish. A popup will indicate that it is
done. In the same folder where the original raw ﬁles are stored, Quant will create a folder for each of your raw ﬁles containing
intermediate results of computations. In addition, a folder ‘combined’ will be generated, which will, after Quant has ﬁnished,
contain output ﬁles ending with .par and .msm; .msm ﬁles contain the processed MS/MS spectra, whereas .par ﬁles carry the
corresponding parameter settings for the Mascot searches. Depending on the SILAC setting, Quant will create one, three or four
kinds of paired .par/.msm ﬁles (Table 2), which differ in the way in which SILAC labeling-related modiﬁcations are treated,
either as ﬁxed or as variable modiﬁcations. As the SILAC state of many isotope patterns is known earlier, the label modiﬁcations
are treated as ﬁxed modiﬁcations in the Mascot search. For unpaired isotope patterns, the search is done in the conventional
way with variable label modiﬁcations.
? TROUBLESHOOTING
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Mascot: MS/MS ion search
18| Once Mascot Daemon is launched, click on the ‘Task Editor’ tab. Insert the name of the task (e.g., ‘test sil0’) into the ﬁeld
entitled ‘Task.’
19| Upload one of the .par ﬁles in the ‘combined’ folder into the ‘Parameter set’ ﬁeld. Upload the corresponding .msm ﬁle(s) by
clicking on the ‘Add Filesy’ button or by using drag&drop from an explorer window. Click on the ‘Run’ button. The display will
switch to the ‘Status’ tab. Once the task is running, the corresponding task icon will change to a clock.
20| Repeat Step 19 with the other ﬁles until all the searches have been submitted.
? TROUBLESHOOTING
21| Once the search is ﬁnished, expand a task node and click on the result node to see the name of the generated .dat ﬁle.
There will be one .dat ﬁle for each .msm ﬁle searched in Mascot.
22| Using an internet browser, go the home page of your Mascot server.
23| In the address bar of the browser, append ‘/data’ at the
end of the address after ‘y/mascot’. For example, if the
address of your Mascot server is http://hansi.biochem.
mpg.de:2000/mascot, go to http://hansi.biochem.mpg.
de:2000/mascot/data. See the MaxQuant website FAQ for
further information.
24| Open the folder with the name of the date when the
search was performed.
25| To save the .dat ﬁle, right click and select ‘Save Target
Asy’. It is convenient (but not required) to save them in the
combined folder containing the other ﬁles of the same project.
Identify.exe: identiﬁcation and validation
26| Locate the program Identify.exe in the ‘MaxQuant’ folder
on the local PC and start it by double clicking it.
27| In the ‘Input ﬁles’ tab, upload the .raw ﬁles that have
been previously run with Quant using either the ‘Select ﬁles’
or the ‘Select folder’ button. The location of this tab, and the
tabs described in later steps, is shown in Figure 3.
28| Upload the .dat ﬁles in the same way.
29| Select the appropriate Protein sequences ﬁle in the
FASTA format.
m CRITICAL STEP On the local computer, one must have exactly
the same sequence database (FASTA) ﬁle as used for the Mascot
database search. Otherwise, Identify will report an error message
and will not be able to ﬁnish.
TABLE 2 | Quant output ﬁles for the submission to Mascot.
SILAC MSM ﬁle PAR ﬁle Description
Singlets test.iso_0.msm test.iso.par MS/MS on single isotope patterns. (No SILAC pair assembly is done)
Doublets test.iso_0.msm test.iso.par MS/MS on single isotope patterns. SILAC labels are treated as variable modiﬁcations
test.sil0_0.msm test.sil0.par SILAC state ‘light.’ No SILAC labels modiﬁcations are used
test.sil1_0.msm test.sil1.par SILAC state ‘heavy.’ Heavy SILAC labels are treated as ﬁxed modiﬁcations
Triplets test.iso_0.msm test.iso.par MS/MS on single isotope patterns. SILAC labels are treated as variable modiﬁcations
test.sil0_0.msm test.sil0.par SILAC state ‘light.’ No SILAC label modiﬁcations are used
test.sil1_0.msm test.sil1.par SILAC state ‘medium.’ Medium SILAC labels are treated as ﬁxed modiﬁcations
test.sil2_0.msm test.sil2.par SILAC state ‘heavy.’ Heavy SILAC labels are treated as ﬁxed modiﬁcations



















Figure 3 | The graphical user interface of the Identify module. The upper
panel shows the ‘Input ﬁles’ tab, whereas in the lower panel, the ‘Parameters’
tab is shown. The positions in the graphical interface of the Identify module
that correspond to numbered steps in the procedure are indicated by the step
number.
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30| Insert the experimental design ﬁle (optional; see Box 1).
31| Go to the ‘Parameters’ tab.
32| Choose the desired FDRs at the protein and peptide levels. For a comprehensive explanation, see ref. 6. The default
value is in both cases 0.01 (1%).
33| Select the desired maximum posterior error probability, which is the probability of a false hit given the peptide
identiﬁcation score and length of peptides6. The default value is 1, corresponding to no additional ﬁltering.
34| Set the minimum peptide length. Peptide shorter than the threshold will not be reported nor be considered for protein
identiﬁcation and quantiﬁcation. Short peptides are usually not unique in the protein database and therefore not statically
informative in any case.
35| Select the minimum number of unique and total peptides a protein group should have to be considered as identiﬁed and
reported in the ﬁnal table.
36| Specify the string for reverse and contaminant hits as used in the protein sequences ﬁle. We usually use ‘REV_’ and ‘CON_’,
respectively.
37| Specify how the protein ratios will be calculated (‘Protein quantiﬁcation’). When ‘Use all peptides’ is selected, the
quantiﬁcation is done on all peptides. With ‘Use unique peptides,’ only the peptides unique for that speciﬁc protein group are
used for quantiﬁcation. The ‘Use unique and razor peptides’ mode calculates ratios from unique and razor peptides.
Razor peptides are non-unique peptides assigned to the protein group with the most other peptides (Occam’s razor principle).
38| Select the minimum ratio count for protein quantiﬁcation. A protein with a lower number of quantiﬁed SILAC pairs/triplets
will not be used for calculating the protein ratio. As ratio counts are reported in the output ﬁles, it is possible to ﬁlter the
results in downstream applications (e.g., Excel).
39| Select the number of parallel threads.
40| Tick the ‘Re-quantify’ box if Identify should calculate the ratio for isotopic patterns not assembled in SILAC pairs by Quant.
The shapes of the identiﬁed isotope pattern will be translated to the place in the m/z retention time plane, where its missing
SILAC partner is expected and intensities will be integrated over these regions. This is particularly helpful for quantifying
proteins with very high ratios, e.g., from pulldowns, where one of the SILAC partners is at or below noise level. However, in
some cases where extreme ratios are expected, e.g., in incorporation studies, we do not recommend using ‘Re-quantify’.
41| If desired, check ‘Keep low-scoring versions of identiﬁed peptides.’ If checked, additional MS/MS spectra will be accepted
beyond those that have individually passed the criteria for identiﬁcation. This means that an MS/MS spectrum will be accepted
even if its posterior error probability value is not sufﬁcient, as long as the highest scoring peptide sequence for that spectrum
has been identiﬁed with another MS/MS spectrum. This has no effect on the total number of identiﬁed peptide sequences or
proteins. This option is particularly beneﬁcial for complex experimental designs, as it increases the likelihood for each protein
of ﬁnding a ratio in different samples or time points.
42| Press the Start button and wait for the program to ﬁnish. A popup will appear when it is done.
? TROUBLESHOOTING
BOX 1 | SPECIFYING THE EXPERIMENTAL DESIGN
To facilitate the inter-sample comparison of protein expression ratios or to assemble data into a speciﬁc form—for instance into a time series—
the software needs to know which LC/MS runs belong to which ‘time point.’ This can be speciﬁed by uploading an experimental design ﬁle in
Step 30. If no experimental design ﬁle is used, SILAC ratios and other protein information are provided as a whole for the entire data set.
A template ﬁle for the experimental design is created automatically in the ‘combined’ folder. Open this template ﬁle in Excel, make appropriate
changes and save it as a tab-delimited text ﬁle. If the ‘Experiment’ column is ﬁlled in, separate average ratios (and other information) will be
reported for each different term used in the Experiment column. For instance, suppose one measures a six-point time course with ﬁve SILAC
experiments by using the time zero sample always as the light state and the samples at ﬁve later time points in the heavy states. In addition,
one may have separated proteins into 10 gel slices, resulting in 50 LC/MS runs. In this case one would ﬁll the ‘Experiment’ column with ﬁve
different terms, which would give rise to an expression ratio matrix with ﬁve columns. In addition, in the ‘Slice’ column denote the numbers
1–10 regarding which gel slice an LC/MS run corresponds to. Additional statistics on slice-speciﬁc identiﬁcations of proteins will then be
provided, which might, for instance, be useful to detect isoforms differing in molecular weight. In the ‘Invert’ column, one can specify if
the ratios originating from certain LC/MS runs should be inverted. This is useful when the labels have been swapped.
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 TIMING
Computation times vary with sample complexity, richness of spectra and LC gradient length. Typical values for 72 LC/MS runs are
Steps 1–17: 10 h; Steps 18–25: 4 h; and Steps 26–42: 2 h.
Almost all algorithmic parts of MaxQuant are parallelized and execution is automatically distributed to the number of speciﬁed
computing cores. Although not tested rigorously, Windows clusters may enhance processing speed signiﬁcantly. Disk access is
likely also limiting and therefore solid-state disks may improve processing speed.
? TROUBLESHOOTING
Troubleshooting advice can be found in Table 3 and in the FAQ on the MaxQuant.org website. For more detailed assistance and
troubleshooting with Mascot and Mascot Daemon, refer to the Mascot manual and support.
TABLE 3 | Troubleshooting table.
Step Problem Possible reason Solution
17 Quant.exe crashes Maximum ﬁle size of 2 GB may be
exceeded
Record MS/MS spectra in the centroid mode
Quant.exe or Identify.exe crashes Storage space may not be enough Use an external disc as storage space
20 Mascot crashes .msm ﬁle may be too big in size Use a maximal msm ﬁle size of 350 MB or even
smaller
42 Identify.exe crashes FASTA ﬁle used for Mascot search
missing on your local computer
Copy the exact same to your local computer
Wrong .dat ﬁles uploaded Check the .dat ﬁle number of your ‘task’ in Mascot
Daemon
Identify.exe reports error of unknown
protein ID
Wrong FASTA ﬁle uploaded Use the same database for the Mascot search and
Identify.exe
Any Unforeseen Unknown First, double check the FAQ on MaxQuant home
page. If still unresolved, describe the problems
in the MaxQuant Google group at http://groups.
google.com/group/maxquant-list
MS/MS, tandem mass spectrometry.
BOX 2 | MAXQUANT OUTPUT TABLES
 parameters.txt—summary of parameters used for analysis
Version number of software used, threshold values used for identiﬁcation and quantiﬁcation, mode of quantiﬁcation and so on
 msScans.txt—full scan summary
Information about the full scan details stored in the raw ﬁle including the ﬁll time and total elapsed time, scan numbers, total ion current, dead
time and so on
 msmsScans.txt—msms scan summary
Consists of the raw ﬁle parameters including the peak type, scan number, total ion count and sequence information wherever there was an
identiﬁcation event
 allPeptides.txt—full scan peptides details
Isotopic clusters, charge state,m/z values. Mass precision, retention time and whether the peptide is picked up for sequencing or not and so on
 msms.txt—summary of scan parameters for identiﬁed peptides
Similar to msmsScans ﬁle but restricted to identiﬁed peptides only
 evidence.txt—one stop master information
Peptide sequence, protein groups a peptide belong to, modiﬁcation state, experiments in which peptide was identiﬁed, PTM score, mass error
calibrated and un-calibrated, MS/MS count, raw ﬁle detail, gel slice/fraction and so on
 peptides.txt—concise non-redundant list of identiﬁed peptide sequences
Peptide sequence, proteins groups that contain the peptide, modiﬁcation, miss cleavages, length of peptide, PEP values and so on.
Identiﬁcation scores for the best-identiﬁed version are displayed
 modiﬁedPeptides.txt—non-redundant list of identiﬁed peptide sequences with speciﬁc modiﬁcations
Peptide sequence, modiﬁcation content, PTM score, intensity, Mascot score and so on
 summary.txt
Overall summary of whole analysis including identiﬁcation success rate for individual raw ﬁles, the percentage of isotopic clusters picked up
for sequencing and isotope patterns repeatedly sequenced
 proteinGroups.txt
Comprehensive list of identiﬁed proteins from the whole analysis, cross-references to various databases including Swissprot, Ensembl, Kegg,
GO and so on
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ANTICIPATED RESULTS
Identify will create several tables as tab-delimited .txt ﬁles that contain the results of the MaxQuant analysis. See Box 2 for a
description of the different output tables. A document with detailed explanation of the columns can be downloaded from the
MaxQuant website. Several annotation columns, such as Gene Ontology27, Pfam28 domain content and KEGG29 pathway
membership, are automatically shown in the table of proteins (Box 3).
A benchmark data set consisting of 72 LC/MS runs from epidermal growth factor-stimulated HeLa cells used in ref. 6 can be
downloaded from http://www.proteomecommons.org/data/show.jsp?id¼7816. Identiﬁcation and quantiﬁcation of more than
4,000 proteins as described in ref. 6 are expected. In another example, Pan et al.16 quantiﬁed the proteome of a cell line against
primary cells of the same cell type. Furthermore, quantiﬁcation of more than 4,000 proteins is expected from the analysis of the
combined data set, which is also deposited at http://www.proteomecommons.org.
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BOX 3 | INTEGRATED PROTEIN ANNOTATION
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 Pfam domain content: Occurrence of protein domain families represented by a hidden Markov model in the Pfam repository is indicated
 Membership of a protein in a KEGG pathway





Systems-wide Analysis of a Phosphatase
Knock-down by Quantitative Proteomics and
Phosphoproteomics□S
Maximiliane Hilger‡, Tiziana Bonaldi‡§, Florian Gnad‡, and Matthias Mann‡¶
Signal transduction in metazoans regulates almost all as-
pects of biological function, and aberrant signaling is in-
volved in many diseases. Perturbations in phosphoryla-
tion-based signaling networks are typically studied in a
hypothesis-driven approach, using phospho-specific an-
tibodies. Here we apply quantitative, high-resolution mass
spectrometry to determine the systems response to the
depletion of one signaling component. Drosophila cells
were metabolically labeled using stable isotope labeling
by amino acids in cell culture (SILAC) and the phospha-
tase Ptp61F, the ortholog of mammalian PTB1B, a drug
target for diabetes, was knocked down by RNAi. In total
we detected more than 10,000 phosphorylation sites in
the phosphoproteome of Drosophila Schneider cells and
trained a phosphorylation site predictor with this data.
SILAC-based quantitation after phosphatase knock-down
showed that apart from the phosphatase, the proteome
was minimally affected whereas 288 of 6,478 high-confi-
dence phosphorylation sites changed significantly. Re-
sponses at the phosphotyrosine level included the already
described Ptp61F substrates Stat92E and Abi. Our analy-
sis highlights a connection of Ptp61F to cytoskeletal reg-
ulation through GTPase regulating proteins and focal ad-
hesion components. Molecular & Cellular Proteomics 8:
1908–1920, 2009.
Information processing in biological systems relies heavily on
activation and inactivation of proteins by phosphorylation. This
key post-translational modification is involved in the regulation
of most cellular processes and mediates many rapid responses
as well as long-term gene expression changes in response to
stimuli. Protein kinases and protein phosphatases coordinately
regulate this highly dynamic and reversible modification. Phos-
phorylation is usually studied in a candidate-based approach by
in vitro kinase assays or by immune techniques employing
phospho-specific antibodies. Despite the success of this reduc-
tionist approach, it does not afford a systems-wide observation
of the effects upon perturbations of signaling networks.
Recent advances in MS-based1 proteomics now allow the
identification of thousands of phosphorylation sites from
complex protein mixtures (1–3). Most large-scale phospho-
proteomics studies have been qualitative rather than quanti-
tative; however, isotope-based methods enable precise
quantitation of phosphorylation sites between two or more
cellular states (4–6). Our group has applied the metabolic
labeling technology termed stable isotope labeling by amino
acids in cell culture (SILAC) (7) for the quantitative comparison
of phosphoproteomes. For example, we quantified phospho-
rylation dynamics in response to epidermal growth factor
stimulation. Out of a measured phosphoproteome of several
thousand sites only a minority (about 10%) was regulated by
the signal, highlighting the importance of quantitation in pin-
pointing specific systems responses (8).
Drosophila is a well established model system to study key
players in cell signaling and development. Genetic studies
have been performed for decades whereas more recently also
RNA interference (RNAi) has been employed for gene function
studies using a highly efficient silencing protocol (9). A further
advantage of Drosophila as a model system is the lower
degree of functional redundancy compared with higher ver-
tebrates while maintaining a high level of conservation of
human genes linked to disease (10).
Two large-scale, non-quantitative Drosophila phosphopro-
teome studies were carried out in embryonic Kc167 cells (11)
and embryos (12). Both studies identified more than 10,000
sites of the Drosophila phosphoproteome.
We have recently adapted the SILAC methodology for
quantitative proteomics to Drosophila. Schneider line 2 (SL2)
cells were treated with either mock dsRNA or dsRNA against
ISWI, a component of chromatin remodeling complexes. The
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combination of RNAi and SILAC allows the unbiased “pheno-
typization” of the gene knock-down directly at the proteome
level (13).
Here we determined a high-quality basal phosphoproteome
in SL2 cells and characterized its structural and evolutionary
properties. We compared kinase substrate motives between
Drosophila and human and trained a Drosophila phosphoryl-
ation site predictor.
To explore the potential of quantitative phosphoproteomics
in a systems-wide manner, we focused on the Drosophila
non-transmembrane tyrosine phosphatase Ptp61F. This
phosphatase is the ortholog of mammalian PTB1B, which is
thought to be involved in type 2 diabetes, obesity, and cancer
(14), and which is the target of several ongoing drug devel-
opment projects (15). Ptp61F is a negative regulator of JAK/
STAT signaling (16, 17) and, together with the Ableson kinase
(Abl), involved in the regulation of the Abl interacting protein
(Abi) and lamella formation (18). Both PTP1B and Ptp61F are
among the best studied protein tyrosine phosphatases in their
respective organisms; however the characterization of their
substrates is still far from complete. Two recent mass spec-
trometric studies employed substrate trapping to identify di-
rect substrates of PTP1B and Ptp61F (19, 20). The PTP1B
study was combined with phosphotyrosine peptide enrich-
ment, which led to site-specific detection of potential PTP1B
targets. PTP1B function was additionally investigated by
quantitative phosphotyrosine proteomics comparing wild
type and PTP1B-deficient fibroblasts. In contrast, the Ptp61F
study identified potential substrates without site-specific in-
formation. One of these was PVR, the Drosophila homolog of
VEGFR and PDGFR, suggesting that Ptp61F - like its mam-
malian counterpart - counteracts receptor tyrosine kinase
signaling. Apart from Abi, further components of the SCAR/
WAVE complex as well as its regulatory kinase Abl were
identified as potential Ptp61F substrates. This supports an
involvement of Ptp61F in the regulation of actin reorganization
and remodeling.
To study the role of Ptp61F in a global and unbiased ap-
proach we combined global quantitative phosphoproteome
analysis with RNA interference. We profiled tyrosine, serine
and threonine phosphorylation changes upon ablation of
Ptp61F by RNAi. In parallel, we quantified changes in the
proteome, which allowed us to normalize changes in phos-
phorylation sites to corresponding changes at the protein
level. Interestingly, we observed increased tyrosine phospho-
rylation of the protein tyrosine kinase Abl which suggests an
enhanced Abl activity upon Ptp61F RNAi. We additionally
detected up-regulated phosphotyrosine sites on GTPase reg-
ulating proteins (like RhoGAP15B and Vav) and constituents
of focal adhesions (like Paxillin and Lasp) which expand the
proposed involvement of Ptp61F in the regulation of cytoskel-
eton organization. Our work represents proof-of-principle that
the combination of large-scale phosphoproteomics and a
loss-of-function approach can contribute significantly to elu-
cidating the role of key players in phosphorylation-dependent
signaling. Importantly, this systems-wide approach measures
the net effect of the perturbation on the entire signaling net-
work, without the need to define specific substrate-kinase or
substrate -phosphatase relationships or other direct func-
tional mechanisms.
EXPERIMENTAL PROCEDURES
Cell Culture—Drosophila Schneider SL2 cells were a kind gift from
Peter Becker’s laboratory. Cells were grown in custom-made Schnei-
der media at 26 °C (13). Schneider media were supplemented by
yeast extract and fetal bovine serum dialyzed overnight using a mo-
lecular weight cutoff of 1.2 kDa to remove free amino acids. “Heavy”
and “light” SILAC media were prepared by adding 0.4 g/liter 13C6
15N4
L-arginine (Arg-10) and 1.65 g/liter 13C6
15N2 L-lysine (Lys-8) (Sigma
Isotec) or the corresponding non-labeled amino acids, 12C6
14N4 L-
arginine (Arg-0) and 12C6
14N2 L-lysine (Lys-0), respectively. Media
were always prepared freshly before the experiments. To obtain two
labeled cell populations the cells were grown for 8–9 days in heavy or
light SILAC media.
Phosphatase Inhibitor Treatment of SILAC-labeled SL2 Cells—SI-
LAC-labeled SL2 cells were treated with an inhibitor mixture for 15
min. The mixture contained 0.3 mM Pervanadate (prepared from 100
mM sodium orthovanadate (Sigma-Aldrich) mixed with 100 mM H2O2),
33 nM Calyculin A (Millipore), and 3 M deltamethrin (Merck).
RNAi of SILAC-labeled SL2 Cells—7.7  106 SL2 cells were re-
suspended in 7 ml of heavy or light serum-free SILAC media and
seeded in a 75 cm2 tissue culture flask. 210-g Ptp61F dsRNA was
added to the heavy or 210-g control GST dsRNA to the light con-
dition, respectively (less than 200 nM). The cells were incubated for
one hour at 26 °C and subsequently 14 ml of heavy or light serum-
containing SILAC media were added. After 4 days two-third of the
SILAC media were refreshed, and after 8 days the cells were har-
vested. The Ptp61F dsRNAs (forward: 5-TTAATACGACTCACTATA-
GGGAGAGGATGTGAATCCGTACGATCAT-3; reverse: 5-TTAATA-
CGACTCACTATAGGGAGAGAACTGCATCACTTCACGACTCT-3)
and GST dsRNAs (forward: 5-TTAATACGACTCACTATAGGGAGAA-
TGTCCCCTATACTAGGTTA-3; reverse: 5-TTAATACGACTCACTAT-
AGGGAGAACGCATCCAGGCACATTG-3) were synthesized accord-
ing to Worby et al. (9) using MEGAshortscript™ kit (Ambion).
Preparation of Cell Extract—Heavy and light SL2 cells were
counted, and equal cell numbers were combined. The cell mixture
was pelleted by centrifugation at 1000 rpm for 5 min, washed with
cold phosphate-buffered saline, and lysed under rotation for 60 min at
4 °C using radioimmune precipitation assay buffer (containing 1%
Triton, 0.1% SDS, 0.1% sodium deoxycholate, 140 mM NaCl, 1 mM
dithiothreitol, 1 mM phenylmethylsulfonyl fluoride, 1 mM EDTA, 10 mM
Tris, pH 8) supplemented with protease inhibitors (complete tablets;
Roche Diagnostics) and phosphatase inhibitors (1 mM sodium or-
thovanadate, 5 mM NaF, 5 mM beta-glycerophosphate). The lysate
was cleared by centrifugation, and the resulting supernatant was
subjected to digestion.
Protein Digestion—For in-gel digestion the whole cell lysate was
separated by one-dimensional SDS-PAGE (4–12% Novex mini-gel;
Invitrogen) and visualized by colloidal Coomassie staining. For the
proteome analysis 100-g whole cell lysate was separated in two
adjacent lanes and identically cut into 15 slices whereas for the
phosphoproteome analysis 300 g of cell lysate was separated in one
lane and cut into 8 slices. All gel slices were subjected to in-gel
digestion with trypsin (21, 22). Resulting tryptic peptides were ex-
tracted with 30% ACN in 3% TFA. For phosphoproteome analysis
extracted peptides were subjected to TiO2 chromatography. For pro-
teome analysis samples were concentrated until full evaporation of
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organic solvent and reconstituted with 1% TFA and 5% ACN. Sub-
sequently peptides were concentrated and desalted on reversed
phase C18 StageTips (23, 24). Peptides were eluted by 30-l buffer B
(80% ACN in 0.5% acetic acid) solution into a sample 96-well plate
(Abgene), concentrated in a SpeedVac until removal of the organic
solvent and reconstituted with a one-to-one mix of buffer A (0.5%
acetic acid) and buffer A* (2% ACN in 1% TFA).
For in-solution digestion whole cell extracts were mixed with four
volumes of ice-cold acetone to precipitate proteins. Precipitated pro-
teins were collected by centrifugation and dissolved in 6 M urea, 2 M
thiourea, 10 mM HEPES or 10 mM Tris and 1% n-octyl glucoside.
2-mg (phosphoproteome with phosphatase inhibitor treatment) or
20-mg proteins (phosphoproteome of Ptp61F RNAi) were reduced
with 1 mM dithiothreitol for 45 min at RT and then alkylated with 5.5
mM iodoacetamide for 30 min. Reduced and alkylated proteins were
digested with 200-g endopeptidase Lys-C (Waco) for 3 h. Subse-
quently the peptide mixture was diluted with four volumes deionized
water and digested with 200-g sequencing grade modified trypsin
(Promega) overnight at RT. Trypsin was inactivated by acidification
with TFA to pH  3, and the peptide mixture was subjected to
phosphopeptide enrichment.
Phosphopeptide Fractionation and Enrichment—Phosphopeptides
were fractionated and enriched from in-solution digested peptides by
the combination of strong cation exchange chromatography (SCX)
and TiO2 chromatography or by multiple rounds of TiO2 chromatog-
raphy in batch mode. Alternatively phosphopeptides were enriched
by TiO2 chromatography from in-gel digested peptide fractions.
SCX was carried out as described (25). The resulting 15 fractions
were pooled according to the 230-nm absorbance intensity. For the
phosphatase inhibitor phosphoproteome experiment 10 fractions and
the flow-through were further enriched for phosphopeptides by TiO2
chromatography (26). For the Ptp61F RNAi experiment 15 fractions
and the flow-through (loading 20 mg at once) and 13 fractions and the
flow-through (performing two separate SCX runs with 10 mg each for
better separation) were subjected to TiO2 chromatography (25). For
the phosphatase inhibitor phosphoproteome experiment both the
TiO2 beads (kindly provided by GL Sciences) and the samples were
pre-incubated with 5 mg/ml 2,5-dihydroxybenzoic acid (DHB) in 80%
ACN before the sample, and5 mg of the TiO2 beads were combined
and incubated batchwise with end-over-end rotation for 1–3 h. For
the Ptp61F phosphoproteome the beads were pre-incubated with 30
mg/ml DHB and added directly to the SCX fraction to reduce the
amount of DHB in the samples.
After incubation, the beads were washed twice with 10% ACN in
0.1% TFA and once with 80% ACN in 0.1% TFA solution. Bound
peptides were eluted from TiO2 beads once with 1% ammonium
solution, pH 10.5, in 20% ACN and twice with 1% ammonium solu-
tion, pH 10.5, in 40% ACN into 20 l of 2% ACN in 1% TFA solution.
Eluates were subsequently dried to 5 l in a SpeedVac and recon-
stituted with 2% ACN in 1% TFA solution for LC-MS/MS analysis.
LC-MS/MS Analysis—The samples were analyzed by a nanoflow
HPLC (Agilent 1100 or 1200; Agilent Technologies) coupled on-line
via a nanoelectrospray ion source (Proxeon Biosystems) to a LTQ-
Orbitrap mass spectrometer (Thermo Fisher Scientific). Peptide mix-
tures were loaded onto a C18-reversed phase column (15 cm long,
75-m inner diameter, packed in-house with ReproSil-Pur C18-AQ
3-m resin) in buffer B with a flow rate of 500 nl/min for 20 min and
eluted with a linear gradient from 2% to 40% buffer B (80% ACN and
0.5% acetic acid solution) at a flow rate of 250 nl/min over two hours.
After each sample the column was washed with 90% buffer B and
re-equilibrated with buffer A.
Mass spectra were acquired in the positive ion mode applying a
data-dependent automatic switch between survey scan and tandem
mass spectra (MS/MS) acquisition. Proteome samples were analyzed
with a top5 method, acquiring one Orbitrap survey scan in the mass
range of m/z 300–2000 followed by MS/MS of the five most intense
ions in the LTQ. The target value in the LTQ-Orbitrap was 1,000,000
for survey scan at a resolution of 60,000 at m/z 400 using lock masses
for recalibration to improve the mass accuracy of precursor ions (27).
Fragmentation in the LTQ was performed by collision-induced dissoci-
ation with a target value of 5,000 ions. Ion selection threshold was 500
counts. Selected sequenced ions were dynamically excluded for 90 s.
For the phosphoproteome acquisition a total scan cycle consisted
of three mass ranges, 350–1050, 850–1750, and 350–1750 with
MS/MS of the five most intense ions for the first two ranges and
MS/MS of the seven most intense ions for the last range. Multi-stage
activation was enabled upon detection of a neutral loss of phosphoric
acid (97.97, 48.99, or 32.66 amu) (28) for further ion fragmentation.
Selected sequenced ions were dynamically excluded for 300 s after
sequencing. Otherwise settings were the same as described before
for the proteome acquisition.
Data Analysis—Mass spectrometric data were analyzed with the
in-house developed software MaxQuant (version 1.0.11.5 for the total
basal SL2 phosphoproteome and version 1.0.12.33 for the spectra
extraction as well as for the proteome and phosphoproteome of
Ptp61F RNAi) (29, 30). MS/MS spectra were searched by Mascot
(version 2.2.04, Matrix Science) against the FlyBase (version 5.4)
(containing 20,822 entries) combined with 175 common contaminants
and concatenated with the reversed versions of all sequences. The
following parameters were set for the Mascot searches. Trypsin al-
lowing for cleavage N-terminal to proline and cleavage between as-
partic acid and proline was chosen as enzyme specificity. Cysteine
carbamidomethylation was selected as a fixed modification, whereas
protein N-terminal acetylation, methionine oxidation and serine, thre-
onine and tyrosine phosphorylation were selected as variable modi-
fications. Depending on a priori knowledge about the number of Arg
and Lys in the precursor ion determined by MaxQuant before the
search, Arg-10 and Lys-8 were used as additional fixed or variable
modifications. Maximally three (version 1.0.11.5) or two missed cleav-
ages (version 1.0.12.33) and three labeled amino acids were allowed.
Initial mass deviation of precursor ion and fragment ions were up to 7
ppm and 0.5 Da, respectively. MaxQuant automatically quantified
SILAC peptides and proteins. SILAC protein ratios were calculated as
the median of all peptide ratios assigned to the protein. A false
discovery rate of 0.01 was required for proteins and peptides with a
minimum length of 6 amino acids. In addition a posterior error prob-
ability for each MS/MS spectrum below or equal to 0.1 was required.
In case the identified peptides of two proteins were the same or the
identified peptides of one protein included all peptides of another
protein, these proteins (e.g. isoforms and homologs) were combined
by MaxQuant and reported as one protein group. Phosphorylation
sites were made non-redundant with regards to their surrounding
peptide sequence. Nevertheless all alternative proteins that matched
a particular phosphosite were reported as one group. The PTM score
was used for assignment of the phosphorylation site(s) as described
(8). Class I phosphorylation sites are defined by a localization prob-
ability of 0.75, and probability localization score difference higher or
equal to 5 (8).
Quantitative RT-PCR—Total RNA was extracted from 1.5-ml cell
suspension 8 days after dsRNA treatment using PrepEaseTM RNA
spin kit (USB). The protocol included a DNA digestion step with
DNase I on the spin column. Reverse transcription was carried out
from 2-g total RNA using first strand cDNA synthesis kit (Fermentas)
according to manufacturer’s protocol with oligo(dT)18 primers. Quan-
titative real-time PCR was performed using iQ™ SYBR Green Su-
permix (BIO-RAD) in the MyiQ Real-Time PCR System (BIO-RAD).
Each reaction mix (25 l) contained 10 ng of cDNA, 12.5 l of SYBER
Green Supermix, and 12.5 pmol of forward and reverse primers. Two
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different primer pairs were used to analyze Ptp61F mRNA levels
(Ptp61F 1 forward: 5-AGCTGCACGATCCCACCTT-3, Ptp61F 1 re-
verse: 5-GTGGCAGATTAAGCGATTGGA-3; Ptp61F 2 forward: 5-
CAGCACGACATGATCCACGA-3, Ptp61F 2 reverse: 5-TGTCGTC-
CTCGTCATCGTCAT-3). GAPDH levels were measured for
normalization via 2CT method (31) (GAPDH forward: 5-ATGAAG-
GTGGTCTCCAACGC-3; reverse: 5-TCATCAGACCCTCGACGA-
TCT-3). Three technical replicates of each sample (Ptp61F RNAi) and
control (GST RNAi) were performed.
Motif Extraction—Motif-X was used to derive potentially new phos-
phorylation motifs in silico and to confirm the observations of the
2-Test. A probability value of 0.0001 was considered significant. In
addition, a minimum occurrence of 20 was required to derive a
significant consensus sequence. The approach was performed resi-
due-specific on all Class I sites using the entire fly proteome as a
background model.
Phosphorylation Site Prediction—A support vector machine was
trained separately for each amino acid on high-confidence phospho-
rylation sites as described in Gnad et al. (32). The essential feature of
each instance that was used for this machine learning approach was
the raw sequence: the phosphorylated residue along with its sur-
rounding sequence (6 residues). This yields 260 dimensions in the
feature space reflecting the surrounding amino acids. Each feature
dimension presents a certain residue on a certain position within the
given 13 amino acid sequence window. To generate a negative set of
the same size, we randomly chose sites from fly proteins that were
not, to date, detected to be phosphorylated. The positive and nega-
tive datasets were split into a training set (90%) and a test set (10%).
The parameters C and  were optimized by varying them from 210 to
210 in multiplicative steps of two on the basis of a 5-fold cross
validation on the training set. The optimal C and  parameters for
predicting phosphoserines were 32 and 0.125, respectively. In the
case of phosphothreonines the best parameters were 4 and 0.125,
respectively. We trained the optimal model for each set of each
phospho amino acid separately using the radial basis function.
Data Availability—Identified phosphorylated peptides and phos-
phorylated sites along with further information ranging from evolu-
tionary conservation to structural constraints and Swiss-Prot anno-
tations were uploaded to Phosida, the phosphorylation site database
(32). Besides the fly phosphoproteome, Phosida also contains phos-
phorylation sites of mouse, human, and various prokaryotes and now
provides the described Drosophila-specific phosphorylation site pre-
dictor. Furthermore, the genome annotation section of Phosida links
directly to the EnsEMBL database, which displays our proteomic data
on the basis of the DAS source management. The setup of Phosida
DAS layers for a given gene of interest in EnsEMBL is described in the
“Background” section of Phosida and in EnsEMBL.
Moreover, the proteomic data (identified peptides) were uploaded
to MAPU - Max-Planck Unified Proteome Database. The detected
peptides, which have been assigned to gene entries as described in
this study, are also available via the MAPU DAS source in the En-
sEMBL database.
RESULTS AND DISCUSSION
High-confidence Determination of the in Vivo SL2 Phospho-
proteome—Most of the phosphoproteomics experiments are
performed in a qualitative manner. Here we employed the
SILAC method instead to measure quantitative changes in the
levels of in vivo phosphorylation sites. In a first SILAC exper-
iment, we compared basal phosphorylation to phosphatase
inhibitor mixture-induced phosphorylation. This involves ap-
plication of cell permeable inhibitors of serine/threonine and
tyrosine protein phosphatases (see below) and has an analyt-
ical rather than a functional goal; it is advantageous because
we trigger the identification of very low abundant endogenous
phosphorylation sites that are up-regulated in response to the
inhibitor treatment. Furthermore, the presence and mass
spacing of the SILAC pair distinguish peptides from noise and
allow counting the number of labeled amino acids, thereby
decreasing the search space in database identification (30).
The second SILAC experiment in which we quantified
changes in the phosphoproteome upon RNAi-mediated
knock-down of a phosphatase (see below) has both an ana-
lytical and a functional goal: it increases the measured en-
dogenous phosphoproteome, which we subsequently ana-
lyzed bioinformatically, and it supplies information on the
cellular roles of the phosphatase. Analytically, these two ex-
periments lead to the detection of different sets of the Dro-
sophila phosphoproteome (Fig. 1 and supplemental Tables 8
and 9). All phosphorylation sites in either SILAC experiments
that are present in the control state (manifest as SILAC pairs)
thus reflect the endogenous phosphorylation status of the
Drosophila SL2 cells here termed “basal phosphoproteome”.
First we SILAC-labeled SL2 cells and treated the heavy cell
population with an inhibitor mixture against serine/threonine
and tyrosine protein phosphatases for 15 min. The two SILAC
populations were combined in equal amounts, and their total
protein extract was in-solution digested. To enrich phos-
phopeptides, we employed both multiple rounds of TiO2 chro-
matography in batch mode and the combination of SCX fol-
lowed by TiO2 chromatography (supplemental Fig. 1).
Phosphopeptide fractions were separated by reverse-phase
chromatography and on-line detected in a high-resolution
linear ion trap-orbitrap instrument (LTQ-Orbitrap) (LC-MS/MS)
(Fig. 1A). A phosphorylation site not responding to inhibitor
treatment is detected as a phosphopeptide peak pair with the
same peak intensities (ratio H/L 	 1). An up-regulated phos-
phorylation site has a ratio H/L
 1 and a down-regulated one
H/L  1. In total, we identified 6,752 high-confidence phos-
phorylation sites (Class I sites: 99% peptide identification con-
fidence and 
75% amino acid localization confidence (8)). Of
the phosphotyrosine sites, 88% were regulated upon phospha-
tase inhibitor treatment whereas only 44% of the phospho-
serine/phosphothreonine sites changed by more than 1.5-fold
(supplemental Fig. 2). This likely reflects the high efficiency of
pervanadate in inhibiting tyrosine phosphatases (33, 34).
Next, we applied quantitative phosphoproteomics to RNAi
of the phosphatase Ptp61F by down-regulating its expression
in the heavy cell population. Cells were SILAC-labeled and
dsRNA treated from the same day because both processes
take about the same number of cell doublings and are com-
pletely independent. Both in-gel digestion coupled with TiO2
chromatography and in-solution digestion in combination with
SCX and TiO2 chromatography were performed (supplemen-
tal Fig. 3). Since dsRNA treatment for 8 days can also alter the
proteome, we additionally analyzed global protein expression
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changes (Fig. 1B). This allows normalization of the phospho-
rylation changes with respect to protein levels.
All quantitative MS data were analyzed together as de-
scribed (29, 30, 33, 35). In total, we detected 10,043 high-
confidence phosphorylation sites on 2,379 phosphoproteins
of which 9,749 were quantifiable and represented our basal
phosphoproteome (supplemental Table 9). This number is
similar to other recent large-scale Drosophila phosphopro-
teome datasets (11, 12). There is a good overlap of phospho-
rylated proteins (65.9% to Zhai et al. 12 and 75.2% to Boden-
miller et al. 11) (supplemental Fig. 4A), especially because the
other investigations used a different cell line (Kc167) under
various conditions or homogenized embryos. However,
while 1,274 phosphorylated proteins were identified in all
three studies, 334 phosphoproteins were exclusively found
in our study indicating that none of the Drosophila phos-
phoproteomes is exhaustive yet. This observation is even
more striking at the level of phosphorylation sites. We de-
tected 4,691 novel phosphorylation sites, while 5,051 sites
(51.8%) were already covered by the other two studies
(supplemental Fig. 4B).
Bioinformatics Analysis of the SL2 Phosphoproteome—In-
sects are at considerable evolutional distance to mammals, in
which most phosphoproteomic studies have been done. Dro-
sophila, in particular, serves as an important model organism,
but so far it is not known how closely the phosphoproteome
FIG. 1. Basal phosphoproteome of Drosophila SL2 cells. A, experimental procedure for quantitative phosphoproteomics with phospha-
tase inhibitor mixture treatment of the heavy labeled SL2 cell population. Phosphopeptides were enriched by applying two different strategies
(supplemental Fig. 1) and analyzed by high-resolution mass spectrometry. B, experimental procedure for quantitative proteomics and
phosphoproteomics in response to Ptp61F deletion by RNA interference. For proteome analysis extracted proteins were digested in gel after
one-dimensional SDS-gelelectrophoresis. For phosphoproteome analysis extracted proteins were both in-gel and in-solution digested and
enriched for phosphopeptides (supplemental Fig. 3).
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resembles that of mammals. We therefore investigated the
overall properties of our high-confidence SL2 phosphopro-
teome using Gene Ontology (GO), kinase motif analysis,
structural constraints, and evolutionary conservation.
Overall Properties of the Drosophila Phosphoproteome Are
Similar to the Human Phosphoproteome—GO cellular com-
partment analysis, using Cytoscape (36) and BiNGO (37),
revealed mitochondria and extracellular compartment to be
underrepresented while nucleus, cytoplasma, and cytoskele-
ton were overrepresented (all with p  0.001) (Fig. 2 and
supplemental Table 1). Regulatory protein classes such as
transcription factors, protein kinases, and GTPase regulating
proteins were highly overrepresented in GO molecular func-
tion analysis (p  1015; supplemental Table 1). Furthermore,
GO analysis after combining our dataset with that of Boden-
miller et al. (11) and Zhai et al. (12) (which yielded 4,871
phosphoproteins), showed similar trends, suggesting they are
valid for the entire Drosophila phosphoproteome (supplemen-
tal Table 2). They also mirror recent analyses of a human and
mouse cell line (8, 33).
Phosphorylation Substrates in Drosophila Can Largely be
Predicted by Human Kinase Motives—To ask whether SL2
phosphorylation sites match significantly with known human
kinase motifs, we employed the 2-Test as described in Pan
et al. (33). The 2-Test assesses the significance of the vari-
ance between observed and expected frequencies. This
showed that fly phosphorylation sites matched significantly to
most of the known kinase motifs, derived from human cells
(supplemental Table 3). As an example, the CDK1 motif p[ST]-
P-X-[KR] matches with the surrounding amino acids of iden-
tified phosphorylation sites six times more frequently than
expected by chance. In the case of human the fold enrich-
ment was twenty.
As described in Schwartz et al. (38), Motif-X is an iterative
approach to derive significantly overrepresented motifs from
large-scale datasets. A motif is built via recursive extraction of
significant amino acid combinations in a given foreground set
(surrounding sequence of phosphorylation sites) compared
with a given background set. The application of Motif-X con-
firmed the findings of the 2-Test (supplemental Table 4). For
example, the second most significant consensus sequence
was the CDK1 motif. We next applied Motif-X to phosphoryl-
ation sites detected in human HeLa cells (8). Overall, 27
significant sequence motifs matched exactly with those de-
rived from the Drosophila set (supplemental Fig. 5) indicating
a high degree of conservation of kinases and their signaling
pathways ranging from CDK to ERK. This is in concordance
with a previous comparison of various eukaryotic kinomes to
the human kinome by Manning et al. (39). For example, fly and
human share several kinase families involved in immunity,
neurobiology as well as basic cellular functions such as the
cell cycle (40).
Phosphorylation Sites Are Largely Confined to Loops and
Hinges on the Protein Surface—Next we assigned secondary
structure and accessibility constraints to phosphorylation
sites employing the prediction method SABLE 2.0 (41). SABLE
assigns the predicted secondary structure (coil, helix, or
-sheet) to each residue of a given input sequence along with
calculated accessibility values ranging from 0 (fully buried) to
9 (fully exposed). As in our previous analysis of the human
phosphoproteome (32), phosphorylation sites are almost ex-
clusively located in coil regions of the surfaces of proteins
(supplemental Fig. 6A). In total, 91% of phosphorylated
serines were found to be located in loop regions in compari-
son to 77% of the serines that were not identified to be
phosphorylated on the same proteins. The resulting degrees
FIG. 2. Over- and under-represented
cellular compartments in the basal
phosphoproteome resulting from
Gene Ontology analysis.
Proteomics Analysis of Phosphatase Knock-down
Molecular & Cellular Proteomics 8.8 1913
of accessibilities calculated by SABLE 2.0 were also signifi-
cantly higher for phosphorylated residues compared with their
non-phosphorylated counterpart (supplemental Fig. 6B). This
is important for kinase and phosphatase substrate accessi-
bility, as well as for subsequent functional effects on the
substrate protein.
Drosophila melanogaster Phosphorylation Site Predictor—
Because none of the Drosophila phosphoproteome datasets
reaches completion, we used a machine learning approach to
predict phosphorylation events in silico (32). We trained a
support vector machine on the full dataset of 7,756 Ser(P),
1,427 Thr(P), and 325 Tyr(P) along with their surrounding
sequences. Serines, threonines, and tyrosines that have not
been proven to be phosphorylated were randomly chosen
from the FlyBase database and defined as negative set. We
used 90% of the given instances for training and 10% for
testing the accuracy of prediction (5-fold cross validation). We
found that 89.8% in the serine set and 81.1% in the threonine
set were predicted correctly (Fig. 3). The accuracy of the
prediction of phosphotyrosines was 63.0%, due to their
smaller number in the training set. Note that this accuracy
assumes equal numbers of phosphorylated and non-phos-
phorylated sites; therefore the accuracy for a given residue in
the proteome will be lower. The predictor may prove useful to
classify potential phosphorylation sites on proteins of interest,
for example, for subsequent mutational studies.
Application of the Drosophila-specific predictor to the hu-
man phospho dataset (8) showed only somewhat inferior per-
formance compared with the predictor trained on human data
(Fig. 3). This further supports the conclusion that human and
insect phosphoproteome are generally similar overall. The
predictor is available online via the Phosida database. Pho-
sida also lists matching kinase motifs for any given predicted
and experimentally found phosphorylation site, thus suggest-
ing potential responsible kinases.
Evolutionary Conservation of the Drosophila Phosphopro-
teome—We used FlyBase (42) to assign our proteomic data to
the genome and EnsEMBL (43) for chromosomal localization.
The SL2 phosphoproteome (quantified and non-quantified
sites) encompassed 2,454 gene transcripts, corresponding to
2,411 distinct genes. For annotation of the Drosophila ge-
nome, we employed the DAS source system using the
Proserver technology (44, 45). This combination allows easy
checking of individual genes and proteins starting from the
genome as well as visualizing overall distribution patterns in
the entire genome. As expected, our dataset did not show a
specific pattern in the genome (supplemental Fig. 7).
The EnsEMBL Compara database contains phylogenetic
relationships between fly and around 40 eukaryotes ranging
from yeast to human. Besides the phylogenetic classifications
between homologous proteins, it also stores global cDNA
alignments. With assigned gene transcripts in hands, we com-
pared the conservation of detected phosphorylated proteins
with the one of all proteins from FlyBase that are defined as
“known” due to former experimental evidence. We found that
phosphorylated proteins show more orthologs throughout all
eukaryotes than all other annotated proteins (supplemental
Table 5 and supplemental Fig. 8). For example, around 70%
of proteins that are phosphorylated in fly have orthologous
counterparts in mosquito; in comparison, around 60% of the
other known proteins are homologous to mosquito proteins.
The same tendency was found for the homology to more
distantly related species such as human or even yeast. The
results of the analysis on the inter-species level are in con-
cordance with ones of the intra-species level. We found that
more than half (55%) of all fly proteins show paralogs,
whereas a mere 27% of the phosphorylated subset shows
homology within the same species. The higher proportion of
non-phosphorylated proteins showing paralogy reflects faster
evolution.
FIG. 3. Precision-Recall curves re-
flecting the accuracy of phospho-
serine and phosphothreonine predic-
tion using the fly-specific predictor.
The recall reflects the proportion of true
positives to the sum of true positives and
false negatives, whereas the precision
describes the number of true positives
out of all predicted positives.
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In addition, we assessed the preservation of the protein
sequence for each homologous protein pair using the rates of
synonymous and non-synonymous base pair substitutions
(dN/dS ratio) (46). The median dN/dS ratio of orthologous phos-
phoproteins was found to be 0.25 compared with 0.33 in the
case of all homologous fly proteins, indicating that there is
negative selection for amino acid changes within the se-
quence of phosphorylated proteins.
In conclusion, evolutionary analysis indicates strong con-
servation of phosphoproteins, presumably because of their
key regulatory functions; for example, in cell signaling. Phy-
logenetic relationships and global alignments between homol-
ogous proteins are displayed in the Phosida database.
Proteome-wide Analysis of Phosphatase Ptp61F RNAi—To
in-depth characterize proteome- and phosphoproteome-wide
responses of the cell to the depletion of the phosphatase
Ptp61F, we combined SILAC-based proteomics with RNA
interference. The quantitative MS data of the proteome and
phosphoproteome analysis of Ptp61F RNAi (Fig. 1B) were
analyzed together as described (29, 30, 33, 35). In total 4,132
proteins were identified with a false discovery rate of 1% and
at least two unique peptides; out of these 3,454 proteins
were quantified with a minimum of three quantitation events
(three SILAC pairs) (supplemental Table 10). The histogram
of the normalized H/L SILAC ratios is shown in Fig. 4A and
is somewhat narrower than a normal distribution, indicating
FIG. 4. RNAi of the tyrosine phosphatase Ptp61F and the effect on the proteome. A, histogram of log2-transformed normalized protein
ratios for all quantified proteins in the Ptp61F RNAi experiment. B, plot of the normalized ratios of all quantified proteins plotted against their
summed heavy and light peptide intensities. C, MS- based analysis of RNAi depletion: a peptide-pair for Ptp61F from the SILAC-based Ptp61F
RNAi proteome experiment, where the phosphatase was depleted in the heavy samples. The Ptp61F peptide (GSVDYINANLVQLER) shows a
heavy to light ratio (H/L) of 0.073 corresponding to a more than 10-fold reduction of the protein level. D, quantitative RT-PCR of Ptp61F
transcript derived from mock control and Ptp61F RNAi cells. Ptp61F mRNA level is reduced to less than 20% by RNA interference. Error bars
represent the standard deviation of three different technical replicates. GAPDH transcript levels were used for normalization.
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that no gross proteome changes occurred. In Fig. 4B the
same ratios are plotted as a function of added peptide
signal. The highest significant outlier is the phosphatase,
which is down-regulated more than 90% (Fig. 4, B and C).
This agrees with 80% decrease of its mRNA in real-time
PCR measurements (Fig. 4D).
The tight distribution around the one-to-one ratio indi-
cates the high accuracy of protein quantitation. We defined
significantly regulated proteins as those that changed at
least 1.5-fold and the fold change of which had an intensity-
dependent statistical significance of at least 0.002 (termed
“significance B”). Applying this level of stringency the de-
tected proteome changes are restricted to sixteen up-reg-
ulated proteins and six down-regulated proteins (supple-
mental Table 6). This suggests - at least at the level of the
proteome that was quantified in our experiments - that the
response to the depletion of the phosphatase has limited
effect at the proteome level, and that our RNAi had few if
any off-target effects. The proteins found up-regulated are
mainly proteins involved in metabolic pathways like the
glycolytic enzyme phosphofructokinase or the glutamine
synthase 2.
An important purpose of the proteome analysis was the
possibility to correct changes at the phosphorylation level by
changes at the protein expression level. In our dataset 77% of
the phosphorylation sites could be normalized to their corre-
sponding protein expression levels (supplemental Table 10).
Interestingly, the remaining phosphorylation sites were not
significantly associated with low intensity phosphopeptides.
Thus they probably reflect the different selectivity of phos-
FIG. 5. Quantitative phosphoproteome upon Ptp61F RNAi. A, plot of normalized ratios of all quantified phosphorylation sites against
their summed heavy and light peptide intensities (n 	 6537). B, SILAC peptide pair of STAT92E, the most up-regulated phospho-
tyrosine peptide upon Ptp61F RNAi. C, SILAC peptide- pair of Abl, 1.9-fold up-regulation on a C-terminal autophosphoylation
site.
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phopeptide enrichment compared with the whole proteome
measurement.
Global Phosphoproteome Response to Ptp61F RNAi—In
total 6,478 phosphorylation sites on 1,904 proteins were de-
tected upon Ptp61F RNAi (supplemental Table 10). Appling
the same criteria as for the proteome, 288 phosphorylation
sites changed significantly, comprising 217 serines, 45
threonines, and 26 tyrosines (Fig. 5A). Thus, in total 4.4% of all
detected phosphorylation sites were affected upon depletion
of a single tyrosine phosphatase. Direct targets of a tyrosine
phosphatase should show up-regulated tyrosine phosphoryl-
ation upon phosphatase RNAi. (Note that we use “up-regu-
lated phosphorylation” to denote increase in phosphorylation
after accounting for protein expression changes.) We de-
tected 15 proteins with 19 up-regulated tyrosine phosphoryl-
ation sites (supplemental Table 7 and Fig. 6). The sole Dro-
sophila Stat (STAT92E) serves as positive control because
Ptp61F is a known suppressor of STAT92E-dependent tran-
scription (16, 17). The phosphorylation site Tyr-704 of this
transcription factor determines its dimerization and accumu-
lation in the nucleus (47, 48). It was found 10-fold up-regu-
lated upon Ptp61F RNAi (Fig. 5B), which represents the most
extreme tyrosine responder in the entire dataset.
One category of proteins with up-regulated tyrosine phos-
phorylation sites are likely direct substrates of Ptp61F be-
cause they are also found in a recent substrate trapping assay
(20). These are the non-receptor protein tyrosine kinase Abl,
its interacting protein Abi (also found by Huang et al. (18)), the
focal adhesion protein Lasp, the GTPase activating protein
RhoGAP15B, and the sorting nexin DSH3PX1. However, the
substrate trapping experiment did not identify specific sites,
and our experiment now provides this important information
(Fig. 6). The kinase Ack was also identified by substrate trap-
ping. The high-confidence tyrosine phosphorylation site Tyr-
987 of Ack was up-regulated 1.3-fold but was not statistically
significant by our definition (Fig. 5A). This was also the case
for the tyrosine phosphorylation sites of SCAR (1.3-fold) and
Pvr (1.2-fold), suggesting that our significant thresholds are
conservative.
The focal adhesion component Paxillin and the guanine-nu-
cleotide exchange factor Vav are potential novel targets of
Ptp61F with a functional link to cytoskeleton organization. In
support, mammalian Paxillin was identified in a PTP1B sub-
strate assay experiment (19). Furthermore, the same study
found increased tyrosine phosphorylation of mammalian Vav3
comparing wild type and in PTP1B-deficient mouse fibroblasts
by quantitative phosphotyrosine proteomics. The tyrosines of
the identified Paxillin and Vav phosphorylation site are con-
served but not yet described as PTP1B target sites. The trans-
lation elongation factor EF1-alpha, the vacuolar protein sorting 4
homolog CG6842, the adaptor protein Dos, the GTPase Rab1,
and Prosap are potential novel Ptp61F substrates with con-
served tyrosine sites in human (supplemental Fig. 10). The pos-
itive regulator of Stat92E-dependent signaling CG15784 and
the guanine-nucleotide exchange factor Tctp are novel potential
substrates where either the protein or the detected regulated
phosphorylation site is not conserved in human.
Our approach is designed to measure systems-wide effects
of pathway perturbation in an unbiased way, rather than to
discriminate direct and indirect actions of the phosphatase. In
addition to up-regulation of direct targets, changes in the
tyrosine phosphorylation levels can also be due to activation
of substrate tyrosine kinases. Illustrating this point, we found
the direct target Abl with increased phosphorylation on Tyr-
540 within the activation loop and on Tyr-1515 within a po-
tential autophosphorylation sequence at the C terminus (Fig.
5C). The activation loop phosphorylation of Abl has been
detected in oncogenic Abl kinases in vivo (49), and this is the
first direct observation of endogenous activation at this site
upon Ptp61F depletion. Enhanced tyrosine phosphorylation
of Abl in general and activation loop phosphorylation in par-
ticular increases its kinase activity (50, 51). Activated Abl
propagates the effects of the Ptp61F RNAi to a second layer
of effector molecules. Several proteins with up-regulated ty-
rosine phosphorylation in our experiment are known to be
phosphorylated by Bcr-Abl or c-Abl in human cell lines. These
include Paxillin (52, 53) and Vav1 (54).
Abi is an interesting example because its phosphorylation
is regulated by both Abl and Ptp61F (18). Thus its increased
phosphorylation upon Ptp61F RNAi is the combined effect
of increased Abl activity and depleted phosphatase. Our in
vivo screen shows that the net effect is a 1.5-fold up-
regulation of Tyr-248. Similarly, the up-regulation of Paxillin
and Vav phosphorylation sites, in our experiment could
reflect the separate or combined action of Abl and Ptp61F.
Since mammalian Paxillin was also identified in a PTP1B
substrate assay experiment (19) a dual action of Abl and
Ptp61F on Paxillin is likely.
With regards to the up-regulation of several metabolic en-
zymes at the protein level, it is interesting that Bcr-Abl signal-
ing has been linked to up-regulation of phosphofructokinase
expression level (55). Furthermore, Bcr-Abl signaling activates
c-Jun NH2-terminal kinase (JNK) (56), possibly providing the
mechanism for increased threonine phosphorylation on the fly
homolog dJun within the transactivation domain (57).
Altogether, we detected 101 up- and 115 down-regulated
phosphorylation sites upon Ptp61F RNAi (supplemental Ta-
ble 7), emphasizing the broad effects of the phosphatase on
the phosphoproteome. There are a number of serine/threo-
nine kinases whose phosphorylation level is altered such as
Fray (1.6-fold up) and MEKK-1 (1.3-fold up), which although
not all passing our threshold for significance could be the
mechanistic link to these broad effects. Note that phos-
phorylation of a kinase can either enhance or inhibit its
activity.
Conclusion—Here we have, for the first time, combined
quantitative proteomics and phosphoproteomics to study
the effects of perturbing phosphorylation-dependent signal-
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ing network by ablating one of its components. This ap-
proach differs from “chemical proteomics” involving ATP-
based enrichment or classical in vitro approaches in that it
measures the net effect of the perturbation on the signaling
network and the expressed proteome in a completely ge-
neric and hypothesis-free approach. Effects on the phos-
phorylation pattern are captured at the quantitative phos-
phoproteomics level, whereas resulting gene expression
changes are measured by quantitative proteomics. These
effects are both upstream and downstream of the interme-
diate output measured by mRNA-based technologies.
We also introduced the concept of parallel acquisition of a
proteome and a phosphoproteome for the system-wide anal-
ysis of a perturbed system. This is generally necessary in
perturbations that last longer than the time required for pro-
tein expression changes (generally 20–30 min) because it
enables assigning changes to the stoichiometry of the phos-
phorylation site (phosphorylation change relative to protein
FIG. 6. Direct and indirect targets of Ptp61F. The H/L phosphopeptide ratios upon Ptp61F RNAi and in brackets their corresponding values
normalized to the protein expression are indicated. Here only phosphotyrosines with normalization and a ratio belonging to a singly
phosphorylated peptide are shown. Tyrosines with asterisk are conserved in human (supplemental Fig. 9).
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amount) and the absolute phosphorylation changes resulting
from a protein expression change. Biologically, the total
amount of phosphorylation, the relative fraction of phospho-
rylation, or both, may be important.
We chose to ablate the Drosophila homolog of a disease
relevant phosphotyrosine phosphatase, Ptp61F by RNAi.
The detected potential substrates were enriched for the
categories cytoskeleton regulation and adhesion signaling
and thus our data further support and expand a role of
Ptp61F in these processes. Our results show a limited effect
of the Ptp61F RNAi on the proteome in contrast to a pro-
nounced effect on the phosphoproteome. This indicates
that the phosphatase predominantly affects phosphoryla-
tion-mediated signaling rather than downstream gene ex-
pression. Therefore a microarray experiment may not have
been efficient at defining the most pertinent effects of this
phosphatase knock-down.
Our proof of principle study clearly demonstrates the power
of combined quantitative proteomics and phosphoproteom-
ics to study system-wide effects of signaling network pertur-
bation. With increasing throughput and automation of MS,
signaling networks could routinely be probed in this way.
Although we used RNAi, other obvious perturbations include
gene knock-outs of kinases and phosphatases as well as
small molecule inhibitors.
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Phosphorylation of SUMO-1 Occurs in Vivo and Is Conserved
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Ivan Matic,† Boris Macek,† Maximiliane Hilger,† Tobias C. Walther,‡ and Matthias Mann*,†
Department of Proteomics and Signal Transduction, Max Planck Institute for Biochemistry, Am Klopferspitz
18, D-82152 Martinsried, Germany, and Organelle Architecture and Dynamics, Max Planck Institute for
Biochemistry, Am Klopferspitz 18, D-82152 Martinsried, Germany
Received May 20, 2008
Protein dynamics is regulated by an elaborate interplay between different post-translational modiﬁca-
tions. Ubiquitin and ubiquitin-like proteins (Ubls) are small proteins that are covalently conjugated to
target proteins with important functional consequences. One such modiﬁer is SUMO, which mainly
modiﬁes nuclear proteins. SUMO contains a unique N-terminal arm not present in ubiquitin and other
Ubls, which functions in the formation of SUMO polymers. Here, we unambiguously show that serine
2 of the endogenous SUMO-1 N-terminal protrusion is phosphorylated in vivo using very high mass
accuracy mass spectrometry at both the MS and the MS/MS level and complementary fragmentation
techniques. Strikingly, we detected the same phosphorylation in yeast, Drosophila and human cells,
suggesting an evolutionary conserved function for this modiﬁcation. The nearly identical human
SUMO-2 and SUMO-3 isoforms differ in serine 2; thus, only SUMO-3 could be phosphorylated at this
position. Our ﬁnding that SUMO can be modiﬁed may point to an additional level of complexity through
modifying a protein-modiﬁer.
Keywords: SUMO-1 • Smt3 • phosphorylation • mass spectrometry • HCD • higher energy dissociation
• evolution • conservation
Introduction
Post-translational modiﬁcations (PTMs) are essential in
virtually every cellular process and often function by modiﬁca-
tion-dependent protein interactions.1,2 Ubiquitin and ubiquitin
like proteins (Ubls) covalently modify target proteins by at-
taching their C-termini to speciﬁc substrate lysines. They are
related by a common tertiary structure, called the ubiquitin
superfold.3 SUMO modiﬁcation regulates the function of target
proteins by modulating protein interactions, intracellular trans-
port, half-life and activity.4 There are three distinct human
SUMO isoforms (SUMO-1, -2, and -3), whereas a single SUMO,
called Smt3, is present in yeast and Drosophila. SUMO-2 and
SUMO-3 are almost identical to each other and 50% identical
to SUMO-1.5 In contrast to ubiquitin and other Ubls, SUMO
proteins contain an unstructured and ﬂexible N-terminal
segment that protrudes from the protein core.6 No functional
differences have yet been demonstrated between SUMO-2 and
SUMO-3, which differ in just three amino acids, all of them
localized on the N-terminal protrusion.
Sumoylation is mediated by an enzymatic mechanism
analogous to ubiquitylation involving three enzymes, namely,
E1, E2 and E3. SUMO-speciﬁc proteases catalyze SUMO
precursor processing and deconjugation of SUMO from modi-
ﬁed substrates.7
Members of the ubiquitin and Ubl family are not only PTMs,
but also proteins that can be targeted by PTMs, raising the
concept of “modiﬁcation of a modiﬁcation”. All seven internal
lysines of ubiquitin can be ubiquitylated,8 of which at least
three have different functional consequences. K11 of SUMO-2
and SUMO-3 is modiﬁed in vivo by SUMO-1 and SUMO-2/3.9,10
Recently, it was shown that K11, K32 and K41 of SUMO-2 can
be modiﬁed by ubiquitin.11,12 This raises the question if SUMO
can also be targeted by PTMs not belonging to the ubiquitin/
Ubl family.
Here, we use a targeted, mass spectrometric approach to
characterize the primary structure of SUMO-1. We report that
the SUMO-1 N-terminal arm is phosphorylated and investigate
the evolutionary conservation of this PTM.
Materials and Methods
Cell Culture and Protein Extraction.HeLa-S3 suspension cells
were grown in RPMI medium containing 10% FBS and 100
units/mL penicillin/streptomycin (Invitrogen), harvested by
centrifugation for 5 min at 400g, washed with cold PBS and
lysed under nondenaturing conditions with lysis buffer (50 mM
HEPES, pH 7.5, 10% glycerol, 150 mM NaCl, 1% Triton X-100,
1 mM EDTA, 1 mM EFTA, 5 mM -glycerophosphate, 1 mM
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NaVO4, 5 mM NaF, complete protease inhibitor mixture
(Roche)). The cell lysate was centrifuged for 1 h at 60 000g at
4 °C and the supernatant was collected.
The YAL6B yeast strain13 was grown in YPD liquid medium
to log-phase (OD600 0.8), harvested by centrifugation for 5 min
at 4000g, washed with cold water and frozen in liquid nitrogen.
The cells were resuspended in lysis buffer (50 mM HEPES, pH
6.8, 150 mM KOAc, 2 mM MgOAc, 5 mM -glycerophosphate,
1 mM NaVO4, 5 mM NaF, complete protease inhibitor mixture
(Roche)) and lysed under nondenaturing conditions using glass
beads. The yeast lysate was centrifuged at 10 000g for 10 min
at 4 °C and the supernatant was collected.
Electrophoresis, Coomassie Staining, and Protein Diges-
tion. Proteins were separated by one-dimensional SDS-PAGE
using Novex 4-12 % precast gels and MES SDS running buffer
(Invitrogen) according to the manufacturer’s instructions. The
gel was stained with Coomassie blue using Colloidal Blue
Staining Kit (Invitrogen). The protein bands in the approximate
molecular weight range 5-20 kDa (Supplementary Figure 1)
were excised from the gel and subjected to in-gel digestion with
trypsin (Promega), essentially as described in Shevchenko et
al.14 The resulting peptide mixture from HeLa cells was cleaned,
desalted, concentrated and enriched using self-made StageT-
ips.15 Phosphopeptides from the yeast mixture were enriched
by titanium dioxide (TiO2) chromatography, as described
previously.16
Mass Spectrometry. LC-MS/MS analysis was performed by
a linear ion trap-orbitrap hybrid mass spectrometer (LTQ-
Orbitrap, Thermo Fisher Scientiﬁc) equipped with a nano-
electrospray ion source (Proxeon Biosystems) and coupled with
an Agilent 1200 nano-HPLC system (Agilent Technologies). The
digested peptides were separated on an in-house packed 75
μm reversed-phase C18 column.17 Survey scan acquisition was
performed in the orbitrap (R ) 60 000 ion accumulation to a
target value of 1 000 000). The ﬁve most intense ions were
fragmented and acquired in the LTQ using collisionally induced
dissociation (CID) (“Full range Top5” method).18 In the second
measurement, the phosphorylated and N-terminally acetylated
peptide of SUMO-1 was analyzed in the selected-ion monitor-
ing (SIM) mode with a scanning range of m/z 932.4-938.4
(R ) 60 000 ion accumulation to a target value of 100 000). The
two most intense ions were isolated and fragmented in the LTQ
using CID and in the C-trap by higher energy CID (HCD). The
acquisition of the resulting MS/MS spectra was performed in
the orbitrap analyzer (R ) 30 000, ion accumulation to a target
value of 75 000) (“SIM CID/HCD” method). Multistage activa-
tion was enable on all CID MS/MS spectra and the lock mass
option was enabled in all measurements to further increase
mass accuracy, as described previously.18
Data Processing and Analysis. Raw data ﬁles were analyzed
with the quantitative proteomics software MaxQuant (version
1.0.9.9),19 which in this case was used for peak list generation,
identiﬁcation and ﬁltering, and Mascot search engine (version
2.2.0; Mascot Science). MS/MS spectra were searched against
the human International Protein Index (IPI) database (Version
3.37),20 the Drosophila proteome database (FlyBase 5.4) or a
yeast Saccharomyces cerevisiae ORF protein database. All three
databases contained the forward and reversed sequences and
were supplemented with the most commonly observed con-
taminants. For database search, enzyme speciﬁcity was set to
trypsin allowing up to three missed cleavages. Carbamidom-
ethylation (C) was set as ﬁxed modiﬁcation, while Oxidation
(M), N-Acetyl (Protein) and phospho (STY) were searched as
variable modiﬁcations. Initial maximum mass deviation was
set to 7 ppm and the fragment ion mass tolerance to 0.5 Da.
The Viewer tool of MaxQuant was used for a 2D and 3D
visualization of LC-MS runs. The signal intensities are color-
coded, with white and black representing the lowest intensities
and green and red the highest intensities, respectively, in the
2D and 3D view.
Multiple sequence alignment was performed using the
ClustalX program.21
Results and Discussion
Phosphorylation of Endogenous Human SUMO-1 in Vivo.
Recent mass spectrometric identiﬁcation of sumoylated and
ubiquitinated SUMO peptides10–12 has induced us to investigate
the possibility that SUMO may be targeted by an additional
major regulatory PTM, phosphorylation.
SUMO is usually prepared for MS analysis from stable cell
lines expressing a tagged form of the protein, such as the His6-
SUMO-2 HeLa cell line.10 These tagged forms have the advan-
tage of good puriﬁcation yield, but also the drawback that
tagged SUMO expressed at nonendogenous levels may behave
differently from its endogenous counterpart. To avoid this and
still obtain sufﬁcient material for analysis, we decided to lyse
cells under nondenaturing conditions. Under these conditions,
cellular SUMO is rapidly deconjugated from target proteins due
to the strong activity of the desumoylation machinery.22
Therefore, previously conjugated SUMO is enriched in the
region of the gel whose molecular weight corresponds to that
Table 1. Detected Phosphorylation Sites from S. cerevisiae and Drosophila melanogaster Smt3 and Human SUMO-1
protein phosphopeptide sequence charge m/z
mass deviation
[ppm] Mascot score intensity acquisition method
SUMO-1 Ac-pSDQEAKPSTEDLGDK 2 871.3618 -0.06 36.93 3.30 × 105 Full range Top5
Ac-SDQEAKPSTEDLGDK 2 831.3787 -1.05 16.39 1.99 × 105 Full range Top5
Ac-pSDQEAKPSTEDLGDKK 2 935.4093 -0.19 35.93 1.04 × 106 Full range Top5
Ac-SDQEAKPSTEDLGDKK 2 895.4262 -0.27 45.45 4.21 × 105 Full range Top5
Ac-pSDQEAKPSTEDLGDKK 3 623.9420 0.05 46.94 6.37 × 105 Full range Top5
Ac-SDQEAKPSTEDLGDKK 3 597.2865 -0.07 48.02 2.40 × 106 Full range Top5
Ac-pSDQEAKPSTEDLGDKK 2 935.4093 0.05 29.78 2.19 × 106 SIM CID/HCD
(from His-SUMO-2) Ac-pSDQEAKPSTEDLGDKKEGEYIK 3 863.7250 0.43 24.76 1.46 × 106 Full range Top5
Ac-SDQEAKPSTEDLGDKKEGEYIK 3 837.0695 0.31 41.87 1.44 × 106 Full range Top5
Yeast Smt3 pSDSEVNQEAK 2 593.7348 -0.47 38.73 8.85 × 104 Full range Top5
Ac-pSDSEVNQEAKPEVKPEVK 3 712.3350 -0.5 34.52 2.13 × 105 Full range Top5
Ac-pSDSEVNQEAKPEVKPEVK 2 1067.9988 -0.52 59.79 2.14 × 105 Full range Top5
Drosophila Smt3 Ac-pSDEKKGGETEHINLK 2 903.9171 -0.77 28.19 7.88 × 105
Ac-pSDEKKGGETEHINLK 3 602.9472 -1.76 21.36 2.71 × 106
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Figure 1. Serine 2 of endogenous human SUMO-1 is phosphorylated in vivo. HeLa total cell lysate was size-fractionated by SDS-PAGE.
(A) Enlarged 2D view of the MS data from the in gel-digested band is shown and the precursor ion isotope distribution is represented
three-dimensionally. Precursor ion was measured in the orbitrap mass spectrometer (m/z 935.4093 (2+); mass deviation, 0.05 ppm),
and the peptide was fragmented by CID in the LTQ (B) and by HCD in the C-trap (C). In both cases, the fragment ions were analyzed
in the orbitrap analyzer. Insets, magniﬁcations of the most intense fragment ion (B) and of the low mass region (C).
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of free SUMO. We lysed HeLa cells, and after separation by
SDS-PAGE, excised and in-gel digested the band in the ap-
proximate range 5-20 kDa (Supplementary Figure 1). Dephos-
phorylation and protein degradation were prevented by adding
phosphatase and protease inhibitors. The resulting peptides
were analyzed by LC-MS/MS on a hybrid linear ion trap-
orbitrap mass spectrometer (LTQ-Orbitrap). We employed the
standard method used in our laboratory, which consists of a
high resolution scan in the orbitrap concurrent with up to ﬁve
low resolution MS/MS scans in the linear ion trap (“Full range
Top5” method, see Materials and Methods).
We found that the N-terminal peptide always lacked the
initial methionine and that it was always N-acetylated in HeLa
cells. This has also very recently been observed by others.23
Unexpectedly, however, this peptide occurred in two forms;
nonphosphorylated or phosphorylated at the N-terminal serine
(Ser2). The charge state of the nonphosphopeptide was pre-
dominantly triply charged, whereas the phosphopeptide was
predominantly doubly charged, presumably because of the
negatively charged phosphogroup (Table 1). To obtain a rough
measure of the stoichiometry of phosphorylation, we integrated
the ion current of the two peptide forms. Often, phosphopep-
tides are assumed to ionize less well than nonphosphopeptides,
although this is not necessarily true.24 Even assuming equal
ionization efﬁciency, our data is consistent with 35-40 % of
Ser2 being phosphorylated. Thus, our data indicates that a large
proportion of SUMO is phosphorylated in vivo.
Because SUMO is the object of intense biological interest
and because no phosphorylation site has yet been described,
we next wanted to conﬁrm the identity of the phosphopeptide
beyond doubt. The identiﬁed phophopeptides of SUMO-1
(Table 1, Supplementary Figures 2-4) had very low mass
deviations from the corresponding calculated values (low ppm
range or below). However, their MS/MS spectra had low
resolution and low mass accuracy (for a direct comparison of
resolutions between orbitrap and LTQ see Matic et al.10).
Unambiguous identiﬁcation of this phosphopeptide was
achieved using the capability of the LTQ-Orbitrap mass spec-
trometer to obtain very high mass accuracy at both MS and
MS/MS level.18 On the basis of the information from the
standard, “Full range Top5” method, we devised a targeted
peptide-speciﬁc method, similarly to the approach used previ-
ously for the identiﬁcation of the SUMO-1/SUMO-2 branched
peptide.10 A narrow mass range of 6 Th around the m/z value
of the precursor ion of interest was monitored in the survey
scan (“SIM CID/HCD” method). The two most abundant peaks
were isolated and fragmented both in the LTQ by CID and in
the C-trap by higher energy dissociation (HCD) (Figure 1). In
the HCD method, the C-trap, which is normally used for storage
of ions prior to injection in the orbitrap, is used to produce
highly efﬁcient quadrupole-like fragmentation.25 The fragment
ions were acquired in the orbitrap producing high-resolution
and high-accuracy MS/MS spectra. Note the similarity of MS/
MS proﬁles in Figure 1, panels B and C. These high resolution
spectra veriﬁed the identity of the b and y ions, crucial for
localizing the modiﬁcation, where b-ions were observed with
loss of phosphoric acid (H3PO4). In particularly, the b3 to b6
ion series in Figure 1A and the b2 ion in Figure 1C, all with
loss of phosphoric acid, as well as the nonmodiﬁed y10 and
y12 ions localize the phosphorylation to the very N-terminus
of the peptide. The fragmentation pathway obtained by HCD
fragmentation in the C-trap also leads to a pronounced internal
fragmentation (Figure 1C), giving rise to the fragment ions in
the low mass part of the spectrum that were absent in CID
fragmentation (Figure 1B). These internal fragments were not
phosphorylated. Low resolution fragmentation spectra of the
peptide with and without missed cleavage further conﬁrmed
the assignments (Table 1 and Supplemental Figures 2-4). In
addition, we also found Ser2 phosphorylation of SUMO-1 in
our previous global study of phosphorylation dynamics during
EGF signaling in HeLa cells.16 Thus, by multiple lines of mass
spectrometric evidence, we unambiguously conﬁrmed that the
endogenous human SUMO-1 is phosphorylated in HeLa cells.
Phosphorylation of Endogenous Human SUMO-1 in His6-
SUMO-2 Conjugates. We next asked if SUMO-1 could be
phosphorylated when conjugated to target proteins. For this
purpose, we interrogated the raw spectra from the His6-
SUMO-2 fraction, in which we had previously detected mixed
SUMO-branched peptides.10 That fraction did not contain any
free SUMO-1 as determined by Western blotting. We reanalyzed
the data with phosphorylation as a variable modiﬁcation and
detected the phosphorylation on SUMO-1 (Supplementary
Figure 8). This shows that SUMO-1 conjugated to target
proteins (likely SUMO-2 in this case) can be phosphorylated.
Identically to the in-gel digested fraction, Ser2 was always
N-terminally acetylated. The nonphosphorylated and phos-
phorylated forms of the peptide have approximately equal
integrated ion current (Table 1), which conﬁrms that a large
fraction of endogenous SUMO-1 is phosphorylated.
Evolutionary Conservation of SUMO Phosphorylation. The
identiﬁed peptides indicate that the N-terminal tail of SUMO-1
undergoes three co- or post-translational modiﬁcations: re-
moval of the starting methionine residue, N-terminal acetyla-
tion and phosphorylation of the ﬁrst amino acid (Ser2) of the
mature SUMO-1. Since Ser2 is in a highly ﬂexible and accessible
part of SUMO-1, this phosphoserine is a good candidate for
the regulation of protein binding (Figure 2A).
To investigate evolutionary conservation of the Ser2, we
aligned the amino acid sequences of SUMOs of ﬁve different
eukaryotic species (Figure 2B). The alignment shows that
Ser2 of human SUMO-1 is conserved in the single SUMO
forms present in S. cerevisiae and D. melanogaster (both
Figure 2. Position of the N-acetylated and phosphorylated residue
and its evolutionary conservation. (A) SUMO-1 structure (1A5R)6
was visualized using ICM Browser Pro (Molsoft, Redmond, WA;
version 3.5-1m). (B) Sequence alignment of the N-terminal arm
of SUMO family.
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called Smt3). In vertebrates, which have three SUMO para-
logs, position 2 is serine in SUMO-1 and SUMO-3, whereas
it is alanine in SUMO-2.
It is interesting to note that the amino acid at position 2 is
one of only three amino acids that are different between human
SUMO-2 and SUMO-3. SUMO-2/3 are so far functionally
indistinguishable, but their sequences are quite different from
SUMO-1. Thus, SUMO-1 and SUMO-3, but not SUMO-2, can
in principle be phosphorylated at their N-terminus.
Despite different strategies, including puriﬁcation of nuclei,
in-solution and in-gel digestion followed by TiO2 enrichment
and the targeted mass spectrometric approach, in this study,
we were not able to detect the SUMO-3 phosphoserine-
containing peptide. Digestion with trypsin could produce a
peptide which is too small to be detected by MS (Figure 3B).
However, the phosphopeptide was not identiﬁed even after
digestion with endoprotease Asp-N, which should produce a
longer and more easily detectable peptide. Our failure may be
due to the low stoichiometry of the modiﬁcation and technical
limitations of our approach and does not prove that SUMO-3
cannot be phosphorylated.
Phosphorylation of Endogenous S. cerevisiae and D. mela-
nogaster Smt3 in Vivo. As mentioned above, Ser2 is evolutionary
conserved in eukaryotic species. To test whether N-terminal
acetylation and phosphorylation of Ser2 are also conserved, we
enriched yeast Smt3 as described for mammalian cells above
and digested the proteins in gel with trypsin. Phosphopeptides
were enriched by TiO2 chromatography and analyzed with the
LTQ-Orbitrap using the standard acquisition method. The
identiﬁed peptide of interest lacks the ﬁrst methione and Ser2
is N-acetylated and phosphorylated (Figure 3, Table 1 and
Supplementary Figures 5 and 6), just as in human SUMO-1.
The presence of the b2 ion with loss of phosphoric acid and of
the unmodiﬁed double charged y16 ion (Figure 3B) excludes
the possibility that the phosphorylation is localized on the
nonconserved Ser4. As in the human case, the N-terminal
Figure 3. Serine 2 of endogenous yeast Smt3 is phosphorylated in vivo. Yeast total cell lysate was separated by SDS-PAGE, the band
was digested in gel, and the phosphopeptides were enriched by TiO2 chromatography. The precursor ion, shown in a 2D and 3D
representation (A), was analyzed in the orbitrap mass spectrometer (m/z 712.3350 (3+); mass deviation, -0.58 ppm), and subsequently
fragmented by CID in the LTQ. The resulting fragmentation spectra were acquired in the LTQ analyzer (B).
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peptide of yeast Smt3 was always lacking the initial methionine,
but contrary to what we observed in HeLa cells, we also
detected a peptide in which Ser2 is phosphorylated, but not
N-acetylated (Table 1, Supplementary Figure 5).
We next interrogated data from an ongoing Drosophila
phosphoproteome project (Hilger et al., manuscript in prepara-
tion). Proteins extracted from Schneider SL2 cells were in-gel
digested and phosphopeptides were enriched by TiO2 chro-
matography. As shown in Figure 4, Table 1 and Supplementary
Figure 7, the N-terminal peptide is acetylated and phospho-
rylated in this species as well.
Conclusions
The ubiquitin and ubiquitin like proteins are unique in that
they are both post-translational modiﬁers but can also them-
selves be modiﬁed. Thus, they have a “modifying” mode, but
also a “modiﬁed” mode. This latter property has only been
explored in depth for ubiquitin and SUMO chain formation.3,9,10
Here, we have shown that a member of the Ubl family, SUMO-
1, is the target of phosphorylation. We used state-of-the-art
high-resolution mass spectrometry at the MS and MS/MS levels
to establish the presence of this modiﬁcation beyond doubt.
Two factors argue that this modiﬁcation may be of functional
signiﬁcance rather than ‘background phosphorylation’. First,
the stoichiometry of the modiﬁcation is highsthe signal of the
phosphopeptide was almost as large as that of the unphos-
phorylated peptide in HeLa cells. It appears unlikely that a
nonfunctional site, especially a highly conserved site potentially
important for protein-protein interaction, would be phospho-
rylated at such high levels. Secondly, we found this modiﬁca-
tion over an evolutionary distance of at least one billion years
and in organisms as different as a unicellular eukaryote, an
insect and human.
Interestingly, a SUMO polymerization site resides within the
amino-terminal arm.10 Here, we have established that two
PTMs not belonging to the ubl/ubiquitin family, namely,
phosphorylation and N-terminal acetylation, contribute to the
SUMO “modiﬁed” mode. The unique feature of the SUMO
proteins compared to other Ubls is the long and very ﬂexible
N-terminal protrusion. It has been suggested that this unstruc-
tured tail of the protein might provide an additional surface
for protein-protein interaction.6 In this perspective, phospho-
rylation of this extreme N-terminal serine could modulate the
ability of proteins to interact with SUMO.
Interestingly, similar amino-terminal tail domains are present
in histones and are essential for chromatin dynamics. Modi-
ﬁcations of histone tails regulate gene expression by mediating
the recruitment of proteins to chromatin.26 The N-terminal
arms of both SUMOs and histones protrude from the protein
core, contain many charged amino acids and different PTMs
sites. Analogously to SUMO, the ﬁrst serine of histones H2A
and H4 are N-acetylated and phosphorylated.27 Thus, one can
speculate that the N-terminal extensions of SUMO may recruit
interaction partners to sumoylated proteins or SUMO itself in
a similar way that histones amino terminal tails recruit proteins
to chromatin.
SUMO-2 and SUMO-3 have yet to be functionally differenti-
ated. All three residues different between these two paralogs
are localized on the N-terminal protrusion and serine is
conserved from SUMO-1 to SUMO-3, but not SUMO-2. The
slight difference in the amino acid sequences between SUMO-2
and SUMO-3 tails and the hypothetical SUMO-3 speciﬁc
phosphorylation could lead to a different recruitment of
Figure 4. Serine 2 of endogenous Drosophila Smt3 is phosphorylated in vivo. Proteins were separated by SDS-PAGE and digested in
gel. Phosphopeptides were enriched using TiO2 beads. The precursor ion was analyzed in the orbitrap mass spectrometer (m/z 903.9171
(2+); mass deviation, -0.77 ppm), and subsequently fragmented and acquired in the LTQ.
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interacting proteins. If regulated Ser2 phosphorylation on
SUMO-3 can be detected, this would be the ﬁrst functional
difference between SUMO-2 and SUMO-3. Thus, the functional
meaning of the phosphorylation on SUMO Ser2 and the
investigation of interaction partners merits further studies.
Abbreviations: PTM, post-translational modiﬁcation; Ubls,
ubiquitin-like proteins; SUMO, small ubiquitin-like modiﬁer;
E1, SUMO-activating enzyme, E2, SUMO-protein carrier pro-
tein; E3, SUMO ligase; LC-MS, liquid chromatography-mass
spectrometry; MS/MS, tandem mass spectrometry; SIM, se-
lected ion monitoring; CID, collision-induced dissociation;
HCD, higher-energy C-trap dissociation; LTQ, linear quadru-
pole ion trap; ppm, parts per million.
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Supporting Information Available: Supplementary
Figure 1, gel region around free SUMO-1 or Smt3 (ap-
proximately 5-20 kDa) was digested in gel and analyzed by
LC-MS/MS; Supplementary Figure 2, MS/MS fragmentation
spectrum of the human SUMO-1 peptide Acetyl-pSDQEAKP-
STEDLGDK. Precursor ion mass was measured in the orbi-
trap analyzer (m/z 871.3618 (2+); mass deviation, -0.06
ppm) and the peptide was fragmented by CID and acquired
in the LTQ mass spectrometer; Supplementary Figure 3, MS/
MS fragmentation spectrum of the human SUMO-1 peptide
Acetyl-pSDQEAKPSTEDLGDKK. Precursor ion mass was
measured in the orbitrap analyzer (m/z 935.4093 (2+); mass
deviation, -0.19 ppm) and the peptide was fragmented by
CID and acquired in the LTQ mass spectrometer; Supple-
mentary Figure 4, MS/MS fragmentation spectrum of the
human SUMO-1 peptide Acetyl-pSDQEAKPSTEDLGDKK.
Precursor ion mass was measured in the orbitrap analyzer
(m/z 623.9420 (3+); mass deviation, 0.05 ppm) and the
peptide was fragmented by CID and acquired in the LTQ
mass spectrometer; Supplementary Figure 5, MS/MS frag-
mentation spectrum of the yeast Smt3 peptide pSDSEVN-
QEAK. Precursor ion mass was measured in the orbitrap
analyzer (m/z 593.7348 (2+); mass deviation, -0.47 ppm)
and the peptide was fragmented by CID and acquired in the
LTQ mass spectrometer; Supplementary Figure 6, MS/MS
fragmentation spectrum of the yeast Smt3 peptide Acetyl-
pSDSEVNQEAKPEVKPEVK. Precursor ion mass was mea-
sured in the orbitrap analyzer (m/z 1067.9988 (2+); mass
deviation, -0.52 ppm) and the peptide was fragmented by
CID and acquired in the LTQ mass spectrometer; Supple-
mentary Figure 7, MS/MS fragmentation spectrum of the
Drosophila Smt3 peptide Acetyl- pSDEKKGGETEHINLK.
Precursor ion mass was measured in the orbitrap analyzer
(m/z 602.9472 (3+); mass deviation, -1.76 ppm) and the MS/
MS spectra were acquired in the LTQ mass spectrometer;
Supplementary Figure 8, His6-SUMO-2 MS/MS data from
Matic et al.10 were analyzed with MaxQuant. MS/MS frag-
mentation spectrum of the human SUMO-1 peptide Acetyl-
pSDQEAKPSTEDLGDKKEGEYIK. Precursor ion mass was
measured in the orbitrap analyzer (m/z 863.7250 (2+); mass
deviation, 0.44 ppm) and the peptide was fragmented by CID
and acquired in the LTQ mass spectrometer. Note that the
multistage activation was not enabled and that the main
fragmentation ion is the neutral loss of the precursor ion.
The enlarged left and right regions of the MS/MS spectrum
show the presence of other fragment ions. This material is
available free of charge via the Internet at http://pubs.
acs.org.
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 Triple SILAC to determine stimulus specific 
interactions in the Wnt pathway 
Maximiliane Hilger§ and Matthias Mann§ 
Many important regulatory functions are 
performed by dynamic multi-protein 
complexes that adapt their composition and 
activity in response to different stimuli. Here 
we employ quantitative affinity purification 
coupled with mass spectrometry to 
efficiently separate background from 
specific interactors but add an additional 
quantitative dimension to explicitly charac-
terize stimulus dependent interactions. This 
is accomplished by stable isotope labeling by 
amino acids in cell culture in a triple-labeling 
format, in which pull-downs with bait, with 
bait and stimulus and without bait are 
quantified against each other. As baits we 
use full-length proteins fused to the green 
fluorescent protein and expressed under 
endogenous control. We applied this 
technology to Wnt signaling, which is 
important in development, tissue homeo-
stasis and in cancer, and investigated 
interactions of the key components APC, 
Axin-1, DVL2 and CtBP2 with differential 
pathway activation. Our screens identify 
many known Wnt complex components and 
link novel candidates to Wnt signaling, 
including FAM83B and Girdin, which we 
found as interactors to multiple Wnt 
pathway players. APC and Axin-1 share 
constitutive interactors but also several bin- 
 
§ From the Department of Proteomics and Signal 
Transduction, Max Planck Institute of Biochemistry, Am 
Klopferspitz 18, D-82152 - Martinsried, Germany 
To whom correspondence may be addressed: Matthias 
Mann, Ph.: 49-89-8578-2557; Fax: 49-89-8578-2219; E-
mail: mmann@biochem.mpg.de 
ders whose binding was modulated by 
stimulation with the ligand Wnt3a. The core 
destruction complex itself, which regulates 
beta-Catenin stability as the key step in 
canonical Wnt signaling, remained essen-
tially unchanged. Girdin binds to DVL2 
independent of stimulation but to Axin-1 
and APC in a stimulus dependent manner. 
Triple SILAC interaction analysis is a 
powerful tool for AP-MS based interaction 
studies that determines specific interactors 
of a protein of interest and at the same time 
resolves stimulus specific interaction 
dynamics. 
The study of protein-protein interactions 
is of pivotal importance because most 
biological functions are mediated by protein 
complexes. In contrast to most other tech-
niques, affinity purification combined with 
mass spectrometry (AP-MS)1 is unbiased in 
that it does not require knowledge of 
potential interaction partners and it can be 
used for systems-wide analysis of protein-
protein interaction networks (1). AP-MS has 
often been performed with the goal of a high 
degree of purification of protein complexes 
using tandem affinity purification (TAP) tag-
ging approaches (2). However, this requires 
1
 The abbreviations used are: AP‑MS, affinity 
purification coupled with mass spectrometry; BAC, 
bacterial artificial chromosome; FDR, false discovery 
rate; GFP, green fluorescent protein; GO, Gene 
Ontology; LTQ, linear trap quadrupole; QUBIC, 
quantitative BAC interactomics; SILAC, stable isotope 
labeling by amino acids in cell culture; TAP, tandem 
affinity purification 
 large amounts of starting material because of 
the two purification steps. Furthermore, the 
stringent washing conditions involved in TAP 
purifications often lead to loss of weakly 
bound protein complex members. Quan-
titative mass spectrometry can overcome 
these limitations by distinguishing specific 
interactors from unspecific background 
binders by the ratios of proteins in bait versus 
control pull-downs (3-5). This allows single-
step low stringent purification and high 
confidence interaction mapping including 
weak interactors.  
There are many different formats for AP-
MS and for quantitative AP-MS (6-11). 
Recently, our laboratory has established an 
integrated workflow for quantitative AP MS 
using bacterial artificial chromosomes (BACs) 
containing the gene of interest fused to the 
green fluorescent protein (GFP), which leads 
to expression of the full-length, GFP-tagged 
proteins from their endogenous promoters 
(12). This system, termed QUBIC for 
QUantitative BAC InteraCtomics, has several 
advantages. Most importantly the bait 
protein is expressed close to endogenous 
levels because the entire gene encoding the 
bait protein, including up- and downstream 
regulatory elements, is stably integrated into 
the genome of the cell (13-16). As tagged 
transcripts and proteins are processed by the 
cell equally to the endogenous counterpart, 
different splice isoforms can be expressed 
and proteins are post-translationally modified 
in the correct manner. Furthermore, cell lines 
expressing tagged versions of very large 
proteins can be created. In contrast to APs of 
the endogenous proteins, the QUBIC strategy 
does not rely on the availability of highly 
specific and immunopreciptating antibodies 
for each protein of interest. 
Most protein complexes, especially those 
with regulatory functions, are dynamic 
structures that form or change their 
composition and activity in response to 
cellular perturbations (17). Stimulation-
dependent changes in protein conformation, 
subcellular localization or modification 
determine the interaction properties of the 
different complex members. Quantitative AP 
MS using stable isotope labeling with amino 
acids in cell culture (SILAC) (18, 19) in a 
double-labeling format is frequently 
employed for the characterization of protein 
interactions. SILAC with three isotope states 
has previously mainly been used to study the 
time dimension of the proteome (20-22) but 
has also enabled differentiation of isoform 
specific interactors (6) and the change in 
composition of RNA polymerase upon 
inhibition of transcription (23).  
Here we wished to establish and 
characterize a general method for 
characterizing constitutive and stimulation 
dependent dynamic interaction partners of 
regulatory protein complexes. We combined 
the QUBIC approach with triple SILAC labeling 
to differentiate background binders from 
specific binders and, in the same experiment, 
constitutive interactors from those that 
associate with a complex in a stimulus 
dependent manner. We applied this method 
to the analysis of complexes in the Wnt 
signaling pathway and investigated 
differential complex formation dependent on 
stimulation of cells with the Wnt ligand 
Wnt3a.  
The canonical Wnt pathway regulates cell 
fate, proliferation and self-renewal of adult 
stem and progenitor cells during the entire 
lifespan of metazoan organisms (24-28). 
Aberrant regulation of this pathway leads to 
different diseases, most prominently sporadic 
colon cancer. The key step in canonical Wnt 
signaling is the regulation of β-Catenin. In the 
absence of Wnt ligands β-Catenin levels are 
low as a result of its continuous 
phosphorylation by the destruction complex, 
which triggers ubiquitylation and subsequent 
proteasomal degradation. Core components 
of the destruction complex are APC 
(Adenomatous Polyposis Coli) and Axin-1, 
which both function as scaffolds, and the 
kinases glycogen synthase kinase 3β (GSK-3β) 
 and casein kinase I-α (CKI-α). Upon Wnt 
ligand binding to the receptors Frizzled and 
LRP5/6, the destruction complex function is 
attenuated, at least in part through 
relocalization to the plasma membrane and 
interactions with Dishevelled (DVL) (24-28). 
Levels of β-Catenin then accumulate in the 
cytoplasm and β-Catenin translocates to the 
nucleus where it binds to TCF/LEF 
transcription factors and coactivates 
transcription of target genes.  
Because of its central importance, the 
Wnt pathway is intensively studied and new 
pathway players that may be potential 
therapeutic targets are still found using a 
variety of approaches (29-31). Although 
canonical Wnt signaling has been investigated 
in depth, the exact mechanism by which the 
destruction complex is inhibited and 
β-Catenin is stabilized is still not fully 
understood. Our Wnt pathway interactome 
study identifies potential novel Wnt pathway 
members and sheds light on the dynamics of 
the complexes involved. 
 
EXPERIMENTAL PROCEDURES 
Cell culture - HeLa cells stably expressing BACs 
with human GFP-tagged APC, Axin-1, DVL2 or 
CtBP2 were grown at 37ºC and 5% CO2 for at least 
five passages in SILAC media (Dulbecco's modified 
eagle medium minus L-arginine and L-lysine 
(Invitrogen) with 10% dialyzed fetal bovine serum 
(Invitrogen) and 100 U/mL penicillin/streptomycin 
(Invitrogen)) containing 73 µg/mL L arginine 
(Arg0) and 49 µg/mL L lysine (Lys0) (light), 73 
µg/mL 13C614N4-L arginine (Arg6) (Euriso-top) 
and 49 µg/mL 4,4,5,5-D4-L-lysine (Lys4) (medium) 
or 73 µg/mL 13C615N4-L arginine (Arg10) and 49 
µg/mL 13C615N2-L Lysine (Lys8) (heavy) each 
supplemented with 400 µg/mL geneticin 
(Invitrogen). The untransfected control HeLa 
Kyoto cells were only light or heavy SILAC labeled. 
Cells were expanded to four, 80% confluent 15 cm 
dishes per affinity purification and per SILAC label 
(in total 12 dishes for one triple SILAC 
experiment). The cell lines were generated by the 
BAC recombineering technology (13, 14) and used 
as transgenic cell pools. 
Wnt stimulation and cell harvest - In the 
‘forward’ experiment heavy labeled transgenic 
cell lines were stimulated for two hours with 200 
ng/mL recombinant mouse Wnt3a (RD Systems), 
dissolved in carrier solution (0.1% BSA in PBS). The 
corresponding medium labeled transgenic cells 
and light labeled untransfected control cells were 
incubated with the carrier solution for two hours. 
In the ‘reverse’ experiment the labels in the 
previous ‘heavy’ and ‘light’ conditions were 
interchanged, whereas the medium labeled 
condition was unchanged. Subsequently cells 
were trypsinized, pelleted, resuspended in PBS 
and counted. Equal cell numbers of each SILAC 
condition were separately pelleted, snap frozen 
and stored at -80°C. 
Preparation of cell extract-Cell pellets were 
thawed on ice and resuspended in 2 mL ice-cold 
lysis buffer (basic buffer (150 mM NaCl, 50 mM 
Tris-HCl (pH 7.5), 5% glycerol), 1% IGPAL-CA-630 
(Sigma), 1 mM MgCl2, 1% Benzonase (Merck) and 
1x EDTA-free complete protease inhibitors 
(Roche). After incubation for 40 min on a rotation 
wheel at 4°C, lysates were centrifuged at 4,000xg 
for 15 min at 4°C. Supernatants were subjected to 
affinity purification. 
Affinity purification - Each cleared SILAC 
extract was incubated separately with 100 µL 
μMACS mouse monoclonal anti-GFP antibody 
coupled magnetic microbeads (Miltenyi Biotech) 
for 15 min. One µColumn (Miltenyi Biotech) per 
SILAC extract was equilibrated with 250 µL basic 
buffer containing 1% IGPAL-CA-630 (Sigma) using 
a hand magnet (Miltenyi Biotech). After 
incubation with the beads, lysates were applied to 
the columns. Subsequently columns were rinsed 
four times with 1 mL basic buffer containing 
0.05% IGPAL-CA-630 (Sigma). For unspecific 
protein elution 25 µL of preheated (95°C) SDS gel 
loading buffer (50 mM Tris HCl (pH 8), 50 mM 
DTT, 1% SDS, 0.005% bromophenol blue, 10% 
glycerol) were added and incubated for 5 min. 
Eluates were collected by adding additional 30 µL 
preheated SDS gel loading buffer to each column. 
Corresponding eluates of the triple SILAC 
experiment and 30 µL NuPAGE LDS sample buffer 
(Invitrogen) were combined. 
Protein digestion - Combined eluates were 
separated by 1D-SDS PAGE (4-12 % Novex mini-
 gel) (Invitrogen) and visualized by colloidal 
Coomassie staining (Invitrogen). Proteins were 
separated in three adjacent lanes that were 
subsequently cut into 8 slices. All gel slices were 
subjected to in-gel digestion with trypsin 
(Promega) (32, 33). Resulting tryptic peptides 
were extracted with 30 % ACN in 3 % TFA, 
concentrated until full evaporation of organic 
solvent and further concentrated and desalted on 
reversed phase C18 StageTips (34, 35). Shortly 
prior to high resolution liquid chromatography 
tandem mass spectrometry (LC MS/MS) analysis 
peptides were eluted twice from the StageTips 
with 20 µL buffer B (80% ACN in 0.5% acetic acid) 
solution into a 96 sample well plate (Abgene), 
concentrated in a SpeedVac concentrator until 
removal of the organic solvent and reconstituted 
with buffer A* (2% ACN in 0.1 % TFA). 
LC-MS/MS analysis - Eluted peptides were 
analyzed by a nanoflow HPLC (Proxeon 
Biosystems) coupled on-line via a nano-
electrospray ion source (Proxeon Biosystems) to a 
linear trap quadrupole (LTQ)-Orbitrap Velos mass 
spectrometer (Thermo Fisher Scientific). Peptide 
mixtures were loaded with an IntelliFlow of 
maximal 500nl/min onto a C18 reversed phase 
column (15 cm long, 75 μm inner diameter, 
packed in-house with ReproSil-Pur C18 AQ 3 μm 
resin (Dr. Maisch)) in buffer A (0.5% acetic acid). 
Peptides were eluted with a multi-segment linear 
gradient of 5–60% buffer B (80% ACN and 0.5% 
acetic acid) at a constant flow rate of 250 nl/min 
over 107 min. Mass spectra were acquired in the 
positive ion mode applying a data-dependent 
automatic switch between survey scan and 
tandem mass spectra (MS/MS) acquisition. A ‘top 
10’ method was applied that acquires one 
Orbitrap survey scan in the mass range of m/z 300 
1650 followed by MS/MS of the ten most intense 
ions in the LTQ. The target value in the LTQ-
Orbitrap was 1,000,000 for survey scan at a 
resolution of 60,000 at m/z 400. Fragmentation in 
the LTQ was performed by collision-induced 
dissociation with a target value of 5,000 ions. The 
ion selection threshold was 500 counts. Selected 
sequenced ions were dynamically excluded for 90 
seconds.  
Data analysis-Raw mass spectrometric data 
were analyzed with the MaxQuant software 
(version 1.0.14.9) (36, 37). A false discovery rate 
(FDR) of 0.01 for proteins and peptides and a 
minimum peptide length of 6 amino acids were 
required. A time-dependent mass recalibration 
algorithm was used instead of lock masses for 
recalibration to improve the mass accuracy of 
precursor ions. MS/MS spectra were searched by 
Mascot (version 2.2.04, Matrix Science) against 
the IPI human data base (version 3.62) (containing 
83,947 entries) combined with 262 common 
contaminants and concatenated with the reversed 
versions of all sequences. For the Mascot search, 
trypsin allowing for cleavage N-terminal to proline 
was chosen as enzyme specificity. Cysteine 
carbamido-methylation was selected as a fixed 
modification, while protein N-terminal acetylation 
and methionine oxidation were selected as 
variable modifications. MaxQuant was used for 
scoring of the peptides for identification. It also 
determined the SILAC state of peptides by the 
mass differences between SILAC peptide pairs and 
this information was used to perform searches 
with fixed Arg6 and Lys4 or Arg10 and Lys8 
modifications as appropriate. Maximally two 
missed cleavages and three labeled amino acids 
were allowed. Initial mass deviation of precursor 
ion was up to 7 ppm, mass deviation for fragment 
ions was 0.5 units on the m/z scale. Protein 
identification required two peptides one of which 
had to be unique to the protein group. 
Quantification in MaxQuant was performed as 
described (36). The ‘Match between runs’ option 
was selected, which enabled the transfer of 
identifications between the MS analysis of the 
same and the adjacent gel slices of all replicates 
and their quantification across the replicates. The 
‘Requantify’ option was enabled, which in effect 
integrates noise levels for undetected SILAC 
partners in order to estimate a lower bound on 
the SILAC ratio. Data analysis plots were either 
performed in the MaxQuant environment 
(Perseus) or in the R environment (38). The label 
swap of the control cell line to light SILAC label 
was additionally used to filter out non-assigned 
contaminants such as rare keratins not contained 
in the contaminant database (Supplemental FIG. 
3). Gene Ontology (GO) analysis was performed 
with AMIGO (39). Cytoscape (40, 41) was used to 
visualize APC and Axin-1 interactome overlap. All 
protein group files, containing the information of 
all protein pull-downs, are uploaded to TRANCHE 
(see instructions at the end of the manuscript). 
 Fluorescence microscopy - HeLa cells stably 
expressing BACs with human GFP-tagged FAM73A 
were grown in 35 mm glass bottom dishes 
(MatTek). After staining cells with MitoTracker 
Red CM-H2XRos (Molecular Probes, Invitrogen), 
cells were imaged with a spinning-disk confocal 
microscope (TiLL iMIC CSU22; Andor) using a back-
illuminated EM charge-coupled device camera 
(iXonEM 897; Andor) and a 60x 1.4 NA oil 
immersion objective (Olympus). 16-bit images 
were collected using Image iQ (version 1.9; Andor) 
in the linear range of the camera. They were 
deconvoluted with Huygens Software and 
cropped with ImageJ (http://rsbweb.nih.gov/ij/). 
 
RESULTS 
Triple SILAC enables detection of 
constitutive and dynamic interactions - We 
established QUBIC (12) in a triple-encoding 
SILAC format to allow analysis of both 
constitutive and dynamic interactions  of bait 
proteins that belong to diverse levels of 
canonical Wnt signaling under differential 
pathway activation. These encompassed APC 
and Axin-1 scaffold components of the 
destruction complex, DVL2, a mediator of the 
Wnt signal from the membrane to the 
destruction complex, as well as CtBP, a 
coregulator of Wnt target gene transcription 
(24-28).  
The cells expressing GFP-tagged protein 
were light (L) and medium (M) SILAC labeled, 
while the control cell line without BAC 
transgene was heavy (H) SILAC labeled (FIG. 
1A). The light labeled transgenic cells were 
stimulated with Wnt3a for two hours. To 
prevent light to heavy or medium to heavy 
exchange of specific interaction partners 
during the immunopurification procedure, 
(42, 43) GFP pull-downs were performed 
separately for each SILAC condition and 
eluates were mixed afterwards. For in-depth 
interactome characterization, we reduced the 
sample complexity by one-dimensional gel 
separation into eight slices. Eluates were 
characterized at high sensitivity on the state-
of-the-art, high-resolution LTQ-Orbitrap Velos 
instrument (44). Detected peptides can be 
classified according to their SILAC triplet peak 
patterns (FIG. 1B). For unspecific background 
binders to either beads or GFP-antibody, this 
pattern shows no change between the three 
states (‘one to one to one’). A specific 
interactor with the GFP-bait will have peptide 
ratios between the pull-down with the non-
stimulated cell population and the 
untransfected control cell population (M/H 
ratio in this case) and/or between the 
stimulated cell population and the control 
(L/H ratio). A stimulus dependent interactor 
has a significant ratio for the peptide 
intensity of the GFP-bait pull-down from the 
stimulated cell population compared to the 
GFP-bait pull-down from the non-stimulated 
cell population (L/M ratio).  
Via a two-dimensional plot proteins can 
be grouped into constitutive interactors and 
dynamic interactors according to the ratios of 
GFP-bait to control cells (here M/H) and GFP-
bait with stimulus to GFP-bait without 
stimulus (L/M). Figure 1C illustrates this 
principle in cartoon form, with outliers in the 
positive x-direction (M/H) representing 
specific binding to the bait protein. This 
dimension contains the information of a 
standard SILAC interaction experiment. 
Plotting the ratio between stimulated and 
non-stimulated cell populations (L/M) on the 
y-axis adds the stimulus dependent 
dimension. Outliers in the positive y-direction 
bind more strongly upon Wnt stimulus, 
whereas outliers in the negative direction 
selectively dissociate from the complex upon 
stimulation. The three main protein classes 
are therefore proteins that bind specifically 
to the bait but not in a signal dependent 
manner (blue oval in FIG. 1C), proteins that 
increase their binding upon stimulation 
(green oval) and proteins that decrease their 
binding (red oval).  
While two of the three possible ratios of 
the triplets are in principle sufficient to 
represent the constitutive and stimulus 
 dependent aspects of interaction, in practice 
all three dimensions are often needed. This is 
because the third ratio can be more 
accurately determined directly rather than 
estimated from the other two. Furthermore, 
proteins that only bind specifically in the 
presence of the stimulus are not optimally 
represented in the graph. They are only 
separated from background binding proteins 
in one dimension (positive outlier on the y-
axis). When plotting stimulus dependent 
binding to control versus stimulus dependent 
binding to non-stimulus dependent binding, 
these proteins are readily separated from the 
origin in both x- and y-directions.  
Heat maps turned out to be a very 
valuable additional visualization method, 
combining all the information from triple 
SILAC pull-downs into a single picture. This 
was particularly true for integrating the data 
from reverse labeling experiments (see 
below). To generate these heat maps, we 
placed all pull-down ratios between the 
triplet states on the horizontal axis and 
performed one-dimensional hierarchical 
clustering of the multiple ratios of each 
quantified prey protein in the vertical 
dimension.  
We typically detected about 1,200 
proteins per pull-down experiment of which 
about 1,100 proteins were quantified with at 
least two ratio counts. These large numbers 
reflect the single step purification procedure 
and our low stringency washing conditions. 
However, the quantitative information 
encoded in the SILAC ratios immediately 
excluded the vast majority of these proteins 
from consideration (typically more than 95% 
of all quantified proteins).  
For each bait, experiments were repeated 
after swapping the SILAC labels between the 
control and the stimulated cell populations. 
This introduced an additional dimension of 
specificity and provided a minimum of two 
biological replicates. Because we required at 
least two peptides and two ratio counts, 
there was a minimum of four data points for 
quantitation per protein. ‘Forward’ and 
‘reverse’ experiments together took 1.5 days 
of measurement time.  
 
APC is an interaction scaffold that is 
altered by Wnt3a stimulation - Adenomatous 
polyposis coli (APC) is a large (~310kDa) 
tumor suppressor protein that is mutated in 
most sporadic colorectal cancers in early 
tumorigenesis. Apart from its role in Wnt 
signaling as a member of the β-Catenin 
destruction complex, APC is involved in 
various other cellular processes such as cell 
migration, cell division, transcriptional 
regulation and DNA repair (45). 
Consequently, it has been reported to be 
localized in many different compartments of 
the cell, including the nucleus, mitochondria, 
mitotic spindle, centrosome, microtubules 
and the plasma membrane. Determination of 
interactors would help to further elucidate 
these diverse APC functions. Previous AP-MS 
of this protein has provided important 
information (29, 30). However, systematic 
study of its interactions has been challenging 
due to its large size (necessitating the use of 
cDNA fragments instead of full-length cDNA) 
and to the difficulty in distinguishing specific 
from non-specific proteins in the absence of 
quantitative methods.  
We analyzed the Wnt3a stimulation 
dependent and independent APC interact-
tome with the triple SILAC strategy described 
above and show the results of one 
experiment in FIG. 2A. More than 1,000 
quantified proteins are plotted according to 
their interaction specificity (x-axis) against 
their stimulus specificity (y-axis). Unassigned 
contaminants are not labeled and are 
therefore readily apparent by their pattern 
after the label-swapping experiment and 
were removed (Supplemental FIG. 3). A large 
majority of proteins cluster around the origin, 
indicating that they bound equally well in the 
presence or absence of the bait and stimulus. 
We extracted the fold-change distribution of 












FIG.1 Analysis of interaction dynamics by QUBIC triple SILAC based quantitative mass 
spectrometry. (A) Experimental workflow for triple SILAC pull-downs to determine Wnt3a dependent 
interaction dynamics. The cell line expressing the GFP-tagged protein of interest is light and medium 
SILAC labeled, the untransfected wild-type control cell line is heavy SILAC labeled. Cells are lysed after 
two hour treatment with Wnt3a (200 ng/mL) or vehicle solution, respectively. GFP-pull-downs are 
performed separately for each SILAC state. Eluates are combined, separated on a one-dimensional gel 
into eight slices and in-gel digested. Resulting peptide mixtures are analyzed by high resolution LC-
MS/MS on an LTQ-Orbitrap Velos. SILAC ratios are automatically quantified by MaxQuant. (B) SILAC 
peptide triplets representing peak profiles characteristic of background, constitutive and dynamic 
binders. The complete elution profile of the isotope cluster of the peptide is shown (m/z scale in x-
direction, elution time in y-direction and MS signal in z-direction). (C) Data analysis plot of the ratio 
representing interaction specificity versus the ratio representing stimulus specificity of the interaction. 
Filled dots represent significant interactors and of these, constitutive interactors are depicted in blue. 
Dynamic interactors with enhanced binding to the bait protein are shown in red and those with reduced 
binding to the bait protein in green. 
 
and determined significant outliers with box 
plot statistics (Supplemental FIG. 2). Many 
proteins are clearly separated from this 
background in the x-direction (specific 
interactors) but not in the stimulus 
dependent dimension. These proteins cluster 
around the x-axis and are colored in blue. 
Eight proteins are in the upper right 
quadrant, indicating that they bound 
specifically to APC and that this binding was 
increased upon Wnt stimulation (colored in 
green). Conversely, there were nine proteins 
whose binding to APC decreased upon Wnt 
stimulation (colored in red, lower right 
quadrant). Interestingly, several proteins 
showed no specific binding to APC without 
stimulus at all but were recruited upon Wnt 
stimulation. As explained above, these 
proteins are more easily visualized when 
using the ratio of binding to GFP-APC with 
Wnt stimulation against control as the x-axis 
(FIG. 2B). In that plot APC binders that are 
 recruited in a stimulus dependent manner 
are located in the upper right quadrant 
(colored in green).  
In total we performed four biological 
replicates, two of these with switched heavy 
and light labels (Experimental Procedures). To 
statistically assess the biological 
reproducibility of the APC interactions, we 
employed a one sample t-test and separately 
plotted the median of all protein ratios from 
the four replicates in volcano plots for the 
cases without and with Wnt stimulation (FIG. 
3A and 3B). This revealed 28 reproducible 
APC interactors (p value < 0.1 combined with 
a minimum ratio of 4). Next, we created a 
heat map of the median ratios of all proteins 
(Supplemental FIG. 5). The 28 reproducible 
APC interactors clustered together in two 
subgroups (FIG. 4). We also visualized the p-
values determined from the t-tests as a heat 
map (FIG. 4). Together, these two heat maps 
conveniently combine the information 
obtained from the replicate triple pull-down 
experiments.  
Our APC interactome includes well-known 
binders such as β-Catenin and the 
transcription regulator CtBP2. It covers 
proteins with GO cellular component 
annotation of all described APC localizations 
(Supplemental Table 1). For example, the 
novel APC interactor Cep170 localizes to the 
centrosome (46) and another novel 
interactor, the kinesin family member KIF2A, 
localizes to microtubules (47). The novel 
protein FAM73A had no known 
compartmental localization. Microscopy of a 
GFP-BAC line of this protein showed co-
staining with mitochondrial outer 
membranes (Supplemental FIG. 4).  
Significant APC binders also include Axin-
1, CKI-α and Wtx, the known binding partners 
of APC in the cytoplasmic β-Catenin 
destruction complex. This complex is usually 
thought to partly disassemble upon Wnt 
stimulation, although evidence against this 
has also been reported (48). Interestingly, in 
our triple SILAC experiments, we did not 
detect dynamic APC interaction changes for 
members of this complex upon Wnt pathway 
activation with Wnt3a, at least not after two 
hours of stimulation. 
While the majority of specific interactors 
showed stimulus independent binding to 
APC, we also identified dynamic interaction 
changes upon Wnt3a activation (FIG. 2 and 4) 
such as the enhanced binding of APC to 
β-Catenin. Since the major mechanism of 
Wnt activation is stabilization of β-Catenin 
leading to its accumulation, this could simply 
be the result of more available β-Catenin. We 
likewise observed increased binding of 
α-Catenin to APC. α-Catenin is reported to 
indirectly associate with APC via β-Catenin 
(49), these three proteins contact each other 
at microtubule ends (50). Cytosolic 
complexes of α- and β-Catenin have also 
been described (51). Thus, dynamic α-Catenin 
binding to APC is most likely due to its 
association with increased levels of β-
Catenin.Furthermore, APC binds β-Catenin 
not only within the destruction complex but 
also in the nucleus to enhance β-Catenin 
nuclear export in the non-Wnt activated cell 
(52).  
Additional dynamic interactors of APC 
with increased binding upon Wnt3a 
stimulation included ATAD3A and ATAD3B. 
These paralogs have been reported to be 
localized in mitochondria, but they expose a 
cytosolic AAA domain (53, 54). ERBB2-
interacting protein (Erbin) is a novel 
interactor, which potentially links APC and 
ERBB2 signaling. Furthermore, there is 
evidence that Erbin binds to β-Catenin and 
negatively regulates Wnt induced gene 
expression (55, 56).  
We identified Girdin as a novel APC 
interactor that exclusively binds upon Wnt3a 
activation (compare FIG. 2 A and B). Girdin is 
a known substrate and regulator of Akt 
signaling (57). Furthermore, Girdin is a 
paralog of Daple, which has been reported to 
interact with the central Wnt signal mediator 
DVL, through its Gly-Cys-Val C-terminal motif
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FIG. 2. Dynamic APC interactome. (A) Results from a triple SILAC pull-down as described in FIG. 1 
using Wnt3a as the stimulus and GFP-APC as bait protein, plotted as explained in FIG. 1C. Annotated 
filled circles represent specific interactors determined by box plot statistics of the fold-change 
distribution of unstimulated pull-down against control. Specific dynamic interactors with enhanced 
binding to APC upon Wnt stimulation are depicted in green; the ones with decreased binding are 
depicted in red. Significance thresholds for dynamic changes were obtained from a box plot of fold-
change distribution of stimulated pull-down against unstimulated pull-down. Constitutive, specific 
interactors are shown in blue. (B) Same experiment as in (A) but with the fold-change distribution of 
stimulated pull-down against control on the x-axis. In this plot dynamic interactors move to the upper 
right hand quadrant as can be seen for the proteins shown in bold. 
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FIG. 3. Volcano plot to determine 
reproducible APC interactors.  
(A) Log2 ratios of the median of four 
pull-downs of GFP-APC against 
control (x-axis) are plotted versus –
log10 of the p-values derived from a 
t-test. Proteins with a minimum four-
fold change combined with a p value 
smaller than 0.1 are considered 
significant (red lines). (B) Same as (A) 





























FIG. 4. Dynamic APC interactome visualized by one-way hierarchical clustering. The three ratios of the 
triple SILAC pull-down (median of four experiments) are used to cluster the reproducible APC interactors 
(determined in FIG. 3) by one-way hierarchical clustering. A green color value signifies specific binding to 
APC without Wnt stimulation (first column) or with Wnt stimulation (second column). The third column 
depicts the SILAC ratio of simulated against unstimulated bait pull-down. In this column a green color 
value represents enhanced binding to APC upon Wnt activation and a red color represents reduced 
binding. Constitutive interactors have no significant ratio and therefore appear in black. Additionally, t-
test results for the ratio reproducibility (FIG. 3) were visualized in another panel after the clustering 
process. Proteins with reproducible ratios are in blue and those below the threshold in yellow. All ratio 
intensities are shown in log scale using the indicated color code. 
 
(57). Interestingly, however, Girdin does not 
have this motif and therefore at least it must 
bind DVL in a different manner. 
In the nucleus APC competes with the 
transcription factor TCF for β-Catenin and the 
APC- β-Catenin complex is then thought to 
bind CtBP2 (58). The APC β-Catenin CtBP2 
complex reduces the pool of β-Catenin that 
can bind to TCF factors and thereby represses 
Wnt-dependent gene expression. The 
transcriptional regulator CtBP2 displays the 
exact opposite APC binding dynamics to 
Girdin. Upon Wnt3a activation, this protein is 
released from its association with APC. 
Colorectal cell lines with truncated APC have 
diminished binding of APC to CtBP2 (58), 
which therefore contributes to increased 
expression of Wnt target genes. Our 
observation that the APC-CtBP2 interaction is 
lost upon Wnt activation demonstrates that 
the truncation of APC is mechanistically 
equivalent to stimulation by the Wnt ligand in 
abolishing CtBP2 binding to the C-terminal 
part of APC.  
Our APC interactome also contained 
WDR26 and MAEA, whose binding was 
diminished upon pathway activation. These 
proteins had previously been found in an 
Axin-1 interaction screen (29). Because APC 
and Axin-1 each have important roles in the 
destruction complex, binders to both proteins 
are more likely to also have Wnt related 
functions. This motivated us to investigate if 
more APC interactors might be linked to Wnt 
signaling in the same way. We therefore 
performed dynamic interaction screens for 
other Wnt signaling components with the aim 
of integrating their interactomes. 
 
The dynamic Axin-1 interactome reveals 
shared APC and Axin-1 interactors linking 
them to Wnt signaling - We determined 
dynamic Axin-1 interactors by triple SILAC 
pull-downs with and without two hour Wnt3a 
activation (FIG. 1A). Experiments were done 
in biological duplicates with switched SILAC 
labeling (Supplemental Table 1 and 
Supplemental FIG. 7). We required a 
minimum ratio of four for significant 
interactors, which was determined from box 
plot statistics. Results are summarized in FIG. 
5A in the heat map format. In total we 
identified 18 specific Axin-1 interactors that 
were present in both duplicates. We 
extensively cover β-Catenin destruction 
complex component members such as APC, 
CKI-α, Wtx, GSK-3β and PP2A, all of which 
turned out to bind constitutively to Axin-1, in 
agreement with a recent report (48). 
Additionally, we found moderately increased 
Axin-1 interaction of SKP1 and β-TrCP2. Both 
of these proteins are members of the 
ubiquitin ligase complex that targets 
β-Catenin for proteasomal degradation (59). 
CDK1δ is known to phosphorylate and 
activate DVL after Wnt3a activation (60, 61) 
and our data show that its binding to Axin-1 
does not depend on Wnt activation. Rho 
GTPase activating protein 21 (RhoGAP21) was 
reported as a β-Catenin interactor on the 
basis of TAP pull-downs (29) and as α-Catenin 
interactor that is required for α-Catenin 
recruitment to adherens junctions (62). We 
identify this protein as a dynamic interactor 
to Axin-1, whose binding is markedly 
enhanced by Wnt activation. Further 
supporting its role in Wnt signaling is the 
observation that RhoGAP21 is also a dynamic 
interactor of APC (Supplemental Table 2). 
However, because of our stringent 
identification criteria it only appears in the 
final Axin-1 and not the APC interactome 
results. 
Comparing the Axin-1 and APC 
interactomes revealed ten shared interactors 
(FIG. 6). Remarkably, the interaction 
dynamics of each shared component with 
either of these proteins was highly similar, 
which suggests that they interact with an 
APC-Axin-1 complex. Among the shared 
interactors are the known destruction 
complex members CKI-α and Wtx as well as 
the ubiquitin ligase component SKP1. We 
detect enhanced binding of β-Catenin to APC 
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and Axin-1, which as noted above may partly 
reflect β-Catenin accumulation upon 
stimulation. Moreover, a complex of these 
three proteins has been reported to localize 
at the membrane after Wnt3a activation (63). 
The interaction of Axin-1 with α-Catenin was 
greatly enhanced by Wnt3a stimulation, 
similar to its binding to APC. Intriguingly 
FIG. 5. Dynamic Axin-1 (A), CtBP2 (B) 
and DVL2 (C) interactomes.  
One-way hierarchical clustering of 
SILAC ratios from biological duplicates 
of triple SILAC experiments performed 
with label switch (FWD and REV 
experiment). The part of the heat map 
with significant ratio intensities is 
depicted. For color coding see FIG. 4.  
 
 Girdin is also a highly significant dynamic 
interactor of Axin-1 and APC upon Wnt3a 
activation. The novel protein FAM83B 
interacts constitutively with both Axin-1 and 
APC. Since we have additionally observed 
interaction of this protein with GSK-3β in 
separate QUBIC experiments (Supplemental 
FIG. 6) , it may be a novel member of the 
destruction complex and is very likely 
involved in Wnt signaling. 
 
The DVL2 interactome reveals constitutive 
binding of Girdin independent of Wnt 
activation – Disheveled (DVL) proteins are 
important Wnt signal mediators that 
counteract destruction complex action upon 
Wnt3a stimulation. The exact mechanism by 
which the Wnt signal is transduced - including 
the complex formation at the membrane, 
which involves phosphorylated DVL - is still 
not fully understood (26). Furthermore, DVL 
proteins integrate different branches of Wnt 
signaling including the planar cell polarity 
(PCP) pathway. Triple SILAC DVL2 pull-downs 
covered known DVL2 binder such as DVL3 
and the positive Wnt regulator CKI-ε (64). The 
negative Wnt PCP regulator Vang-like protein 
1/ Strabismus 2 (65, 66), was also a significant 
interactor of DVL2. None of the ten identified 
interactions were modulated by the Wnt 
signal (FIG. 5B, Supplemental FIG. 8). Among 
the newly discovered interactors, we found 
the three members of the BTB/POZ domain-
containing protein family KCTD10/KCTD13/ 
TNFAIP1 (67). We detect Girdin as a novel 
and specific interactor for DVL2. In contrast 
to its dynamically increased binding to APC 
and Axin-1 upon Wnt3a stimulation, Girdin 
binds constitutively to DVL2.  
 
CtBP2 binds to β catenin in a non-stimulus 
dependent manner - We determined the 
dynamic CtBP2 interactome to characterize a 
potentially dynamic nuclear regulator of Wnt 
signaling. We detected 12 specific interactors 
of CtBP2 but none of them with significant 
stimulus dependent changes (FIG. 5C, 
Supplemental FIG. 8). Among these was β 
catenin, which is known to interact with 
CtBP2 as well as with APC to repress 
transcription of Wnt target genes (see also 
above). Upon Wnt stimulation β catenin 
interacts with CtBP2 and TCF to contribute to 
transcriptional activation (68). Our 
observation that the β catenin–CtBP2 
interaction is not dynamically regulated by 
Wnt, agrees with suggestions that these two 
proteins function in both repression (58) and 
activation of gene expression (68). The 
majority of specific CtBP2 interactors were 
members of complexes that deposit 
activating or remove repressive histone 
methylation marks (69, 70). This concords 
with known CtBP2 functions and interactions, 
which are broad and not only specific to Wnt 
signaling (71). 
 
DISCUSSION AND OUTLOOK 
Here we have described a three-state 
quantitative proteomics approach to study 
the dynamics of protein-protein interactions. 
We used the SILAC technology because of its 
simplicity and accuracy of quantification 
when coupled to a high resolution mass 
spectrometric readout. Proteins were 
expressed as GFP fusions from bacterial 
artificial chromosomes that had been 
integrated into the host cell genome, 
ensuring close to endogenous expression 
levels, correct modification state and 
compartmentalization of the bait proteins. 
This is especially important for studying a 
signaling pathway such as Wnt, in which the 
regulation of protein amount is critical and in 
which the signal propagates through different 
cellular locations. The approach described 
here is generic as BAC-GFP cell lines can be 
produced in a streamlined procedure (16). 
We employed one-dimensional gel separa-
tion using somewhat more material (four 15 
cm dishes per condition) than in single run 
analyses  (12).  Analysis  of  the  results  was
  
 
Fig. 6. Overlap of APC and Axin-1 interactomes. Protein-protein interactions were drawn in Cytoscape, 
after importing the pull-down data from FIG. 4 and FIG. 5A. Baits are depicted in yellow, shared APC and 
Axin-1 interactors in blue and unique interactors for APC and Axin-1 in purple and pink, respectively. 
Lines represent detected interactions. Green lines indicate enhanced interaction upon Wnt3a activation 
while red lines indicate reduced interactions upon Wnt3a activation. Line width reflects the SILAC ratio 
intensity for the dynamic interactors. 
 
   
  more complex than double-labeling SILAC 
because three states are compared. 
However, these analysis steps have now been 
incorporated into the freely available 
MaxQuant environment or as R-scripts. 
Consequently, dynamic analysis of interaction 
partners is relatively streamlined and it can 
now be used routinely for pathways of 
interest or as a follow up on initial high-
throughput protein interaction screens.  
There are several obvious extensions of 
the workflow described here. For example, 
dynamic interaction measurements can be 
repeated at different time points to 
investigate the changing composition of 
signaling complexes over time. In this 
experiment the three SILAC states can each 
represent different time points because the 
specificity of the binders has already been 
established.  
Here we have applied the QUBIC triple 
SILAC dynamic interaction screen to the 
challenging case of Wnt signaling. We 
performed pull-downs on central members of 
the pathway from the destruction complex 
and from other different pathway levels. The 
SILAC ratios efficiently filtered out non-
specific binders, reducing an initial set of 
about 1,000 identified proteins to a relatively 
small number (10 to 50). These proteins 
contained many positive controls that were 
either known interaction partners or that 
already had some other connection to Wnt 
signaling. Among the novel interaction 
partners we focused on those shared by APC 
and Axin-1, which are most likely to be 
functional members of the Wnt pathway. 
Interestingly, almost all of these interaction 
partners turned out to have similar 
interaction dynamics, consistent with a role 
in a shared complex with APC and Axin-1. 
Other dynamic interaction partners of APC or 
Axin-1 are also good candidates for functional 
roles in this pathway by virtue of their Wnt-
dependent interaction modulation.  
One example is Girdin (CCDC88A), which 
we separately found as a novel interactor of 
APC, Axin 1 and Disheveled 2 (DVL2). 
Intriguingly, interaction with APC and Axin-1 
are contingent on Wnt-stimulation, whereas 
interaction with DVL2 is not. This raises the 
possibility that Girdin and DVL2 are in a pre-
formed complex, which may then recruit 
destruction complex members to the 
membrane receptors upon Wnt pathway 
stimulation. In this context, we observed that 
interaction of APC and Axin-1 with other 
destruction complex members did not change 
upon Wnt3a activation. This finding sheds 
some light on the unresolved mechanism of 
destruction complex dynamics at the plasma 
membrane. In concordance with recent 
observations (48), our data is consistent with 
a potential translocation of a relatively intact 
destruction complex, at least after two hours 
of Wnt stimulation.  
The majority of colon cancers have a 
truncated form of APC. This interferes with 
APC’s role in the destruction complex. 
Additionally, truncated APC loses binding to 
CtBP2, diminishing its repressor function (58). 
Our data show that CtBP2 binding to full 
length APC is entirely Wnt-dependent. This 
implies that colon cancer cells could also lose 
this binding by another manipulation of the 
Wnt signal cascade, different from APC 
truncation.  
In conclusion, we have described a 
streamlined interaction screen, which 
accurately discriminates constitutive from 
dynamic, signal dependent interactions. In 
contrast to targeted techniques, such as 
western blotting, it can both discover and 
characterize such dynamic interactors in the 
same experiment. Interaction proteomics is 
now clearly ready to add a dynamic 
dimension to protein interaction studies.  
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